<!DOCTYPE html>
<!-- saved from url=(0065)https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm -->
<html class="">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
      <title>Non-ST-elevation myocardial infarction - Treatment algorithm | BMJ Best Practice</title>
      <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
      <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
      <meta name="apple-itunes-app" content="app-id=1105379489">
      <meta name="description" content="Part of the acute coronary syndrome spectrum. Usually caused by a partial or near-complete occlusion of a coronary artery resulting in compromised blood flow to myocardium with subsequent myocardial injury or infarction as demonstrated by elevation in troponin. There are differences in typical pr...">
      <meta name="author" content="Cody S. Deen">
      <!-- Optimize Page Hiding Snippet --> 
      <!-- <style>.async-hide
         { opacity: 0 !important}
      </style>
      <script async="" src="./151_NSTEMI_management_treatment_algorithm_files/adrum-ext.0086dbec5e8a6e717bf36d3a06b62042.js"></script><script src="./151_NSTEMI_management_treatment_algorithm_files/414393182248444" async=""></script><script async="" src="./151_NSTEMI_management_treatment_algorithm_files/fbevents.js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_treatment_algorithm_files/analytics.js"></script><script async="" src="./151_NSTEMI_management_treatment_algorithm_files/get-loader.js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_treatment_algorithm_files/insight.min.js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_treatment_algorithm_files/js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_treatment_algorithm_files/uwt.js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_treatment_algorithm_files/4896.js"></script><script type="text/javascript" async="" src="./151_NSTEMI_management_treatment_algorithm_files/analytics.js"></script><script async="" src="./151_NSTEMI_management_treatment_algorithm_files/gtm.js"></script><script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date; h.end=i=function()
         {s.className=s.className.replace(RegExp(' ?'+y),'')}
         ; (a[n]=a[n]||[]).hide=h;setTimeout(function()
         
         {i();h.end=null}
         ,c);h.timeout=c;})(window,document.documentElement,'async-hide','dataLayer',3000,
         
         {'GTM-K3TZ3JV':true}
         );
      </script> -->
      <!-- end Optimize Page Hiding Snippet -->
      <!-- Google Tag Manager -->
      <script>
         /*<![CDATA[*/
         
          
         window.dataLayer = window.dataLayer || [];
         window.dataLayer.push({
                    'icsId': "id6370964",
                    'pi_icsId': "id82087",
                    'pi_icsName': "BMJ Group (Online access from BMA House)",
                    'access_rights': true,
                    'ics_groupings': [{"name":"Country Grouping"},{"name":"bmj.com:registrant"},{"name":"bp-institutional-users:registrant"}],
                    'ics_countryName': "GB and ROW",
                    'siteLanguage': "en-gb",
                    'contentLanguage': "en-gb"
                 });
         		  
         /*]]>*/
            
      </script>
      <script>
         (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
         new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
         j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
         'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
         })(window,document,'script','dataLayer', 'GTM-K3TZ3JV');
      </script>
      <!-- End Google Tag Manager -->
      <!-- /* if user in China */ -->
      <link rel="stylesheet" type="text/css" media="screen" href="../css/material.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/styles.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/external.css">
      <link rel="shortcut icon" href="https://resources.bmj.com/repository/images/favicon.ico">
      <link rel="canonical" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm">
      <link rel="alternate" hreflang="uk-ua" href="https://bestpractice.bmj.com/topics/uk-ua/151/treatment-algorithm">
      <link rel="alternate" hreflang="en-ie" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm">
      <link rel="alternate" hreflang="az-az" href="https://bestpractice.bmj.com/topics/az-az/151/treatment-algorithm">
      <link rel="alternate" hreflang="en-us" href="https://bestpractice.bmj.com/topics/en-us/151/treatment-algorithm">
      <link rel="alternate" hreflang="ru" href="https://bestpractice.bmj.com/topics/ru-ru/151/treatment-algorithm">
      <link rel="alternate" hreflang="pt" href="https://bestpractice.bmj.com/topics/pt-br/151/treatment-algorithm">
      <link rel="alternate" hreflang="ka-ge" href="https://bestpractice.bmj.com/topics/ka-ge/151/treatment-algorithm">
      <link rel="alternate" hreflang="pt-br" href="https://bestpractice.bmj.com/topics/pt-br/151/treatment-algorithm">
      <link rel="alternate" hreflang="en" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm">
      <link rel="alternate" hreflang="es-es" href="https://bestpractice.bmj.com/topics/es-es/151/treatment-algorithm">
      <link rel="alternate" hreflang="zh-cn" href="https://bestpractice.bmj.com/topics/zh-cn/151/treatment-algorithm">
      <link rel="alternate" hreflang="zh" href="https://bestpractice.bmj.com/topics/zh-cn/151/treatment-algorithm">
      <link rel="alternate" hreflang="es" href="https://bestpractice.bmj.com/topics/es-es/151/treatment-algorithm">
      <link rel="alternate" hreflang="x-default" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm">
      <link rel="alternate" hreflang="ru-ru" href="https://bestpractice.bmj.com/topics/ru-ru/151/treatment-algorithm">
      <link rel="alternate" hreflang="vi" href="https://bestpractice.bmj.com/topics/vi-vn/151/treatment-algorithm">
      <link rel="alternate" hreflang="uk" href="https://bestpractice.bmj.com/topics/uk-ua/151/treatment-algorithm">
      <link rel="alternate" hreflang="ka" href="https://bestpractice.bmj.com/topics/ka-ge/151/treatment-algorithm">
      <link rel="alternate" hreflang="az" href="https://bestpractice.bmj.com/topics/az-az/151/treatment-algorithm">
      <link rel="alternate" hreflang="vi-vn" href="https://bestpractice.bmj.com/topics/vi-vn/151/treatment-algorithm">
      <link rel="alternate" hreflang="en-gb" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm">
      <!--[if lte IE 9]>
      <link rel="stylesheet" type="text/css" media="screen" href="/gzip_1791a8687c5480ce19e791d0825e7a6b/css/lte-ie-9.css" >
      <![endif]-->
      <script>
         /*<![CDATA[*/
           var appdynamics_app_key="AD-AAB-AAF-RGR";
         /*]]>*/
           	window["adrum-app-key"] = appdynamics_app_key;
           	window['adrum-start-time'] = new Date().getTime();
           
      </script>
      <script type="text/javascript" src="../js/appdynamics.js"></script>
      <script type="application/ld+json">
         [
         
         { "@context": "http://schema.org", "@type": "MedicalCondition" }
         ,{
         "isAccessibleForFree": "False",
         "hasPart":
         
         { "@type": "WebPageElement", "isAccessibleForFree": "False", "cssSelector" : ".gpw" }
         }]
      </script>
      <meta name="msvalidate.01" content="76FD53F39FDFB050A93D7925608BA016">
      <style type="text/css">._6772342E312E39_src-lib-Adapter-styles__centerStyle--2U8wI, ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M, ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio, ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw {
         top: 50%;
         position: absolute;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1 {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         box-sizing: border-box;
         padding: 0;
         border-radius: 3px;
         position: fixed;
         display: block;
         visibility: visible;
         bottom: 0;
         background-color: #f3f3f3;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, -webkit-transform 0.1s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.1s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.1s 0s ease-in-out, -webkit-transform 0.1s 0s ease-in-out;
         z-index: 99999;
         box-shadow: 0px 0px 5px 1px rgba(0, 0, 0, 0.18);
         overflow: hidden;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dragging--2uZno {
         transition: opacity 0.1s 0s linear;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__closed--eHbpJ {
         visibility: hidden;
         opacity: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__loading--1ewAG {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         position: relative;
         height: 35px;
         line-height: 35px;
         min-width: 165px;
         text-align: center;
         cursor: move;
         z-index: 11;
         overflow: hidden;
         font-family: Helvetica;
         font-weight: normal;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         cursor: ew-resize;
         }
         ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         left: 50%;
         height: 16px;
         width: 100px;
         margin-top: -8px;
         margin-left: -50px;
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         left: 20px;
         height: 14px;
         width: 14px;
         border-radius: 8px;
         margin-top: -7px;
         display: none;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__dropdownPresence--18mrh {
         display: none;
         position: absolute;
         width: 100%;
         height: 100vh;
         }
         ._6772342E312E39_src-lib-Adapter-styles__showDropdown--242EQ {
         display: block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceItem--3ODPj {
         padding: 10px 15px;
         display: block;
         cursor: pointer;
         text-decoration: none;
         text-align: left;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceItem--3ODPj:hover {
         background-color: #f5f5f5;
         }
         ._6772342E312E39_src-lib-Adapter-styles__selected--1z5-3 {
         color: #0684bd;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM {
         position: relative;
         width: 160px;
         min-width: 165px;
         left: 5px;
         padding: 0;
         min-height: 30px;
         box-sizing: border-box;
         box-shadow: 0 0 4px 0 rgba(0, 0, 0, 0.2);
         background-color: #ffffff;
         border-style: solid;
         border-width: 0;
         border-top-width: 1px;
         border-bottom-width: 0px;
         border-color: #eeeeee;
         border-radius: 4px;
         font-family: "Helvetica Neue", Helvetica, Arial, sans-serif;
         font-size: 14px;
         color: #2F2F2F;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__horizontal--1DydQ {
         display: inline-flex;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__clickable--G0zEI {
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__noborder--1ysDv {
         border: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         left: 10px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Offline--3PnxB {
         display: block;
         background: #cdcdcd;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Busy--IDedL {
         display: block;
         background: #f95b5c;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Available--2GLYE {
         display: block;
         background-color: #32ae31;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         display: none;
         position: absolute;
         width: 8px;
         height: 2px;
         border-radius: 1.5px;
         background-color: #ffffff;
         -webkit-transform-origin: 50% 50%;
         transform-origin: 50% 50%;
         -webkit-transform: translate(3px, 6px);
         transform: translate(3px, 6px);
         }
         ._6772342E312E39_src-lib-Adapter-styles__DoNotAcceptAnyCalls--1WuKo {
         display: block;
         background: #f95b5c;
         }
         ._6772342E312E39_src-lib-Adapter-styles__DoNotAcceptAnyCalls--1WuKo ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         display: block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__statusIcon--2SoFd {
         display: inline-block;
         position: relative;
         margin-right: 5px;
         top: 2px;
         left: 0;
         margin-top: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw {
         box-sizing: border-box;
         height: 20px;
         width: 20px;
         margin-top: -12px;
         border-radius: 3px;
         cursor: pointer;
         border-style: solid;
         border-width: 1px;
         border-color: transparent;
         }
         ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw:hover {
         border-color: #cccccc;
         }
         ._6772342E312E39_src-lib-Adapter-styles__toggle--2EHo_ {
         right: 40px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__toggle--2EHo_ {
         right: 3px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimizeIcon--NnVNt {
         position: absolute;
         box-sizing: border-box;
         left: 3px;
         bottom: 7px;
         width: 12px;
         height: 2px;
         border: 1px solid #888888;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__minimizeIcon--NnVNt {
         height: 12px;
         bottom: 3px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimizeIconBar--2WYhn {
         width: 100%;
         height: 1px;
         background-color: #888888;
         }
         ._6772342E312E39_src-lib-Adapter-styles__close--1qEO1 {
         right: 16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__close--1qEO1 {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR {
         position: relative;
         overflow: hidden;
         margin: 2px;
         width: 14px;
         height: 14px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :first-child, ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :last-child {
         position: absolute;
         height: 2px;
         width: 100%;
         top: 6px;
         left: 0;
         background: #888888;
         border-radius: 1px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :first-child {
         -webkit-transform: rotate(45deg);
         transform: rotate(45deg);
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :last-child {
         -webkit-transform: rotate(-45deg);
         transform: rotate(-45deg);
         }
         ._6772342E312E39_src-lib-Adapter-styles__contentFrame--Z6dLx {
         display: block;
         border: none;
         width: 0;
         height: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__frameContainer--Wtvcz {
         overflow: hidden;
         transition: width 0.1s 0s ease-in-out, height 0.1s 0s ease-in-out;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__glow--1aZft {
         0% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         40%, 50% {
         box-shadow: inset 0 0 7px 0px #0684bd;
         }
         100% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__glow--1aZft {
         0% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         40%, 50% {
         box-shadow: inset 0 0 7px 0px #0684bd;
         }
         100% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__ringing--2c7d0 {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__glow--1aZft;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__glow--1aZft;
         -webkit-animation-duration: 2s;
         animation-duration: 2s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: infinite;
         animation-iteration-count: infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         0% {
         display: none;
         top: -50%;
         }
         100% {
         display: inline-block;
         top: 50%;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         0% {
         display: none;
         top: -50%;
         }
         100% {
         display: inline-block;
         top: 50%;
         }
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         0% {
         display: inline-block;
         top: 50%;
         }
         100% {
         top: 150%;
         display: none;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         0% {
         display: inline-block;
         top: 50%;
         }
         100% {
         top: 150%;
         display: none;
         }
         }
         ._6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz;
         -webkit-animation-duration: 1s;
         animation-duration: 1s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: 1;
         animation-iteration-count: 1;
         -webkit-animation-fill-mode: forwards;
         animation-fill-mode: forwards;
         }
         ._6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa;
         -webkit-animation-duration: 1s;
         animation-duration: 1s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: 1;
         animation-iteration-count: 1;
         -webkit-animation-fill-mode: forwards;
         animation-fill-mode: forwards;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5, ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS {
         position: absolute;
         top: -50%;
         left: 50%;
         height: 16px;
         line-height: 16px;
         margin-top: -8px;
         color: #666666;
         font-size: 12px;
         white-space: nowrap;
         width: 33px;
         margin-left: -60px;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS._6772342E312E39_src-lib-Adapter-styles__center--3fFya {
         margin-left: -16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV {
         position: absolute;
         top: -50%;
         left: 50%;
         height: 16px;
         line-height: 16px;
         margin-top: -8px;
         color: #666666;
         font-size: 12px;
         white-space: nowrap;
         width: 100px;
         margin-left: -100px;
         text-overflow: ellipsis;
         overflow: hidden;
         text-align: center;
         }
         ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV._6772342E312E39_src-lib-Adapter-styles__center--3fFya, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV._6772342E312E39_src-lib-Adapter-styles__center--3fFya {
         margin-left: -50px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX {
         position: absolute;
         top: -50%;
         left: 50%;
         padding: 0 5px;
         height: 18px;
         line-height: 18px;
         border-radius: 10.5px;
         font-size: 11px;
         margin-top: -10px;
         margin-left: -13px;
         overflow: hidden;
         white-space: nowrap;
         min-width: 66px;
         max-width: 110px;
         cursor: pointer;
         border: solid 1px #5FB95C;
         color: #5FB95C;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         margin-top: -10px;
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX:hover {
         color: #5FB95C;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         margin-left: -80px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL {
         position: absolute;
         top: -50%;
         left: 50%;
         padding: 0 5px;
         height: 18px;
         line-height: 18px;
         border-radius: 10.5px;
         font-size: 11px;
         margin-top: -10px;
         margin-left: -13px;
         overflow: hidden;
         white-space: nowrap;
         min-width: 66px;
         max-width: 110px;
         cursor: pointer;
         border: solid 1px #FF8800;
         color: #FF8800;
         margin-left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL:hover {
         color: #FF8800;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         margin-top: -10px;
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__detectNew--2RyZg {
         background: url("https://rc-hack-new.detect");
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1 {
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, width 0.2s ease-in-out, -webkit-transform 0.2s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.2s 0s ease-in-out, width 0.2s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.2s 0s ease-in-out, width 0.2s ease-in-out, -webkit-transform 0.2s 0s ease-in-out;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC {
         top: initial !important;
         width: 300px;
         border-top-right-radius: 0;
         border-bottom-right-radius: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg {
         width: 60px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__noPresence--gCXYu {
         width: 35px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         opacity: 1 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         opacity: 0 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M {
         opacity: 1 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__expandable--1dLZX {
         width: 140px !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         line-height: initial;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         width: 12px;
         height: 12px;
         margin-top: -6px;
         z-index: 2;
         transition: .2s;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         -webkit-transform: translate(2px, 5px);
         transform: translate(2px, 5px);
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M._6772342E312E39_src-lib-Adapter-styles__dock---5JfC {
         opacity: 0;
         transition: opacity .2s;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         z-index: 2147483648;
         top: 7px;
         position: absolute;
         left: 30px;
         height: 22px;
         width: 22px;
         display: block;
         cursor: pointer;
         opacity: 1;
         transition: .3s;
         display: flex;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv ._6772342E312E39_src-lib-Adapter-styles__icon--2I9x4 {
         width: 22px;
         height: 22px;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv._6772342E312E39_src-lib-Adapter-styles__noPresence--gCXYu {
         left: 7px !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__frameContainer--Wtvcz {
         overflow: hidden;
         transition: width 0.2s 0s ease-in-out, height 0.2s 0s ease-in-out;
         }
         ._6772342E312E39_src-lib-Adapter-styles__popOut--2sH2z {
         right: 16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__popOut--2sH2z {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__popOutIcon--oudoy img {
         position: absolute;
         top: 3px;
         left: 1px;
         width: 14px;
         }
      </style>
      <style type="text/css">._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         display: none;
         height: 30px;
         left: 0;
         position: fixed;
         top: 0;
         -webkit-transform: opacity 0.1s 0s linear;
         transform: opacity 0.1s 0s linear;
         z-index: 999999999;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         background-color: rgba(255, 255, 255, 0.95);
         box-sizing: border-box;
         border: 1px solid #cfcfcf;
         border-radius: 4px;
         font-size: 0px;
         height: 30px;
         white-space: nowrap;
         margin: 0 0 0 5px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 img {
         vertical-align: baseline !important;
         display: inline-block !important;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 {
         margin: 0 5px 0 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr {
         position: absolute;
         border-top: 5px solid transparent;
         border-bottom: 5px solid transparent;
         border-right: 5px solid #cfcfcf;
         top: calc(50% - 5px);
         left: 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO {
         position: absolute;
         border-top: 5px solid transparent;
         border-bottom: 5px solid transparent;
         border-right: 5px solid #FF8800;
         top: calc(50% - 5px);
         left: 1px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr {
         border-right: none;
         border-left: 5px solid #cfcfcf;
         left: initial;
         right: 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO {
         border-right: none;
         border-left: 5px solid #fff;
         left: initial;
         right: 1px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dLogo--3d0gU {
         height: 30px;
         width: 30px;
         margin: -1px 0 0 -1px;
         vertical-align: baseline;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v {
         display: block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc {
         display: none;
         position: relative;
         vertical-align: top;
         cursor: pointer;
         font-size: 18px;
         height: 28px;
         width: 28px;
         line-height: 28px;
         text-align: center;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK:hover, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI:hover, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc:hover {
         opacity: 0.6;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7 {
         display: none;
         width: 1px;
         height: 19px;
         margin: 5px 0;
         background: #cdcdcd;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7:hover {
         opacity: 0.6;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__hack--5AVJK {
         background: url("https://rc-hack-c2d.detect");
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK svg, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI svg, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc svg {
         position: absolute;
         top: 50%;
         left: 50%;
         -webkit-transform: translateX(-50%) translateY(-50%);
         transform: translateX(-50%) translateY(-50%);
         overflow: visible !important;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK svg > path, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI svg > path, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc svg > path {
         fill: #0684bd;
         stroke: #0684bd;
         }
      </style>
      <style type="text/css">add-meeting-button {
         line-height: 36px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__root--3CtVK {
         margin-left: 8px;
         position: relative;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q {
         min-width: 94px;
         white-space: nowrap;
         height: 26px;
         line-height: 26px;
         padding: 0;
         font-size: 11px;
         font-weight: 500;
         text-align: center;
         color: #0684bd;
         background: #fff;
         border-radius: 20px;
         border: 1px solid #9bcee5;
         font-family: Roboto, Helvetica, Arial, sans-serif;
         font-weight: 400;
         outline: none;
         cursor: pointer;
         transition: .3s;
         display: none;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q:hover {
         color: #fff;
         background-color: #9bcee5;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q._6772342E312E39_src-lib-MeetingHelper-Page-styles__disabled--12Fo1 {
         color: #fff;
         background-color: #c7c7c7;
         border: 1px solid #c7c7c7;
         cursor: default;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q._6772342E312E39_src-lib-MeetingHelper-Page-styles__disabled--12Fo1:hover {
         cursor: default;
         background-color: #c7c7c7;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__or--Hsdgj {
         float: left;
         margin-left: 10px;
         font-size: 12px;
         color: #0684bd;
         display: none;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__icon--r7sAL {
         left: 5px;
         top: 4px;
         width: 18px;
         height: 18px;
         position: absolute;
         background: #fff;
         border-radius: 100%;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__text--1nLnV {
         width: 100%;
         margin-left: 25px;
         padding-right: 6px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__meetingContainer--24va2 {
         display: flex;
         flex-grow: 100;
         align-items: center;
         }
      </style>
      <style type="text/css">#rc-meeting-popup-window {
         width: 100%;
         height: 100%;
         background-color: rgba(0, 0, 0, 0.3);
         display: flex;
         justify-content: center;
         align-items: center;
         line-height: normal;
         text-align: left;
         position: fixed;
         z-index: 2147483647;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__container--2qd2O {
         width: 470px;
         height: auto;
         display: flex;
         flex-direction: column;
         align-items: stretch;
         overflow: hidden;
         box-shadow: 0 24px 38px 3px rgba(0, 0, 0, 0.14), 0 9px 46px 8px rgba(0, 0, 0, 0.12), 0 11px 15px -7px rgba(0, 0, 0, 0.2);
         border-radius: 2px;
         position: relative;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__header--axhLA {
         position: relative;
         width: 100%;
         height: 30px;
         line-height: 30px;
         font-size: 12px;
         box-sizing: border-box;
         background: #ffffff;
         padding-left: 15px;
         padding-top: 10px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__recurringMeetingPrompt--3U97a {
         margin: 5px 22px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__closeBtn--1JJ_X {
         position: absolute;
         top: 13px;
         right: 15px;
         color: rgba(0, 0, 0, 0.54);
         fill: rgba(0, 0, 0, 0.54);
         width: 20px;
         height: 20px;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__closeBtn--1JJ_X svg {
         width: 20px;
         height: 20px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__wrapper--3DttD {
         background-color: #ffffff;
         width: 100%;
         padding: 10px;
         box-sizing: border-box;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__settings--15yhX {
         border-radius: 3px;
         box-sizing: border-box;
         padding: 0 8px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__categoryLabel--2n8iQ {
         margin: 10px 0;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__categoryWrapper--2LA96 {
         border-radius: 3px;
         background-color: #F9F9F9;
         border: 1px solid #E2E2E2;
         padding: 9px 16px;
         box-sizing: border-box;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__settingLabel--ybCle {
         display: inline-block;
         width: 80px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF {
         line-height: 20px;
         margin: 7px 0;
         display: flex;
         align-items: center;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF * {
         vertical-align: middle;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__video--1oJss {
         margin-left: 15px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__audio--2dr2m {
         margin-left: 15px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF input:first-of-type {
         margin-left: 0;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__controls--1GgrW {
         margin: 10px 0 10px 10px;
         height: 30px;
         line-height: 30px;
         display: flex;
         align-items: center;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__schedule--3SMpg {
         background: #4285f4;
         color: #fff;
         transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
         box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14), 0 3px 1px -2px rgba(0, 0, 0, 0.12), 0 1px 5px 0 rgba(0, 0, 0, 0.2);
         border: 0;
         border-radius: 3px;
         cursor: pointer;
         display: inline-block;
         font-weight: 500;
         outline: none;
         overflow: hidden;
         text-align: center;
         z-index: 0;
         font-size: 12px;
         line-height: 30px;
         height: 32px;
         min-width: 88px;
         position: absolute;
         right: 18px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__header--axhLA span {
         font-size: 16px;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__password--3Ij_s {
         display: none;
         margin-left: 10px;
         }
      </style>
      <style type="text/css">._6772342E312E39_src-lib-MeetingHelper-Spinner-styles__spinner--18fX2 {
         -webkit-animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP 1.4s linear infinite;
         animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP 1.4s linear infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP {
         0% {
         -webkit-transform: rotate(0deg);
         transform: rotate(0deg);
         }
         100% {
         -webkit-transform: rotate(270deg);
         transform: rotate(270deg);
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP {
         0% {
         -webkit-transform: rotate(0deg);
         transform: rotate(0deg);
         }
         100% {
         -webkit-transform: rotate(270deg);
         transform: rotate(270deg);
         }
         }
         ._6772342E312E39_src-lib-MeetingHelper-Spinner-styles__path--2xqMm {
         stroke-dasharray: 187;
         stroke-dashoffset: 0;
         -webkit-transform-origin: center;
         transform-origin: center;
         -webkit-animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k 1.4s ease-in-out infinite, _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q 5.6s ease-in-out infinite;
         animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k 1.4s ease-in-out infinite, _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q 5.6s ease-in-out infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q {
         0% {
         stroke: #4285F4;
         }
         25% {
         stroke: #DE3E35;
         }
         50% {
         stroke: #F7C223;
         }
         75% {
         stroke: #1B9A59;
         }
         100% {
         stroke: #4285F4;
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q {
         0% {
         stroke: #4285F4;
         }
         25% {
         stroke: #DE3E35;
         }
         50% {
         stroke: #F7C223;
         }
         75% {
         stroke: #1B9A59;
         }
         100% {
         stroke: #4285F4;
         }
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k {
         0% {
         stroke-dashoffset: 187;
         }
         50% {
         stroke-dashoffset: 46.75;
         -webkit-transform: rotate(135deg);
         transform: rotate(135deg);
         }
         100% {
         stroke-dashoffset: 187;
         -webkit-transform: rotate(450deg);
         transform: rotate(450deg);
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k {
         0% {
         stroke-dashoffset: 187;
         }
         50% {
         stroke-dashoffset: 46.75;
         -webkit-transform: rotate(135deg);
         transform: rotate(135deg);
         }
         100% {
         stroke-dashoffset: 187;
         -webkit-transform: rotate(450deg);
         transform: rotate(450deg);
         }
         }
      </style>
      <style></style>
   </head>
   <body class="gpw">
      <div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc" class="cc-window cc-banner cc-type-info cc-theme-classic cc-bottom cc-color-override--38786966 " style="">
         <!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our 
         <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link" href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">cookies policy</a></span>
         <div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0" class="cc-btn cc-dismiss">OK!</a></div>
         <!--googleon: all-->
      </div>
      <!-- Google Tag Manager (noscript) -->
      <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K3TZ3JV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <!-- End Google Tag Manager (noscript) -->
      <!-- /* if user in China */ -->
      <header id="header" role="banner">
         <a class="sr-only" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#sr-content">Skip to main content</a>
         <div class="bg-info text-white">
         </div>
         <nav id="globalNav" class="logo-img-mob navbar navbar-toggleable-md">
            <div class="container">
               <a href="https://bestpractice.bmj.com/" class="mobLogo"><span class="remove"><abbr>BMJ</abbr> Best Practice</span></a>
               <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
               <span class="material-icons"></span>
               </button>
               <div id="navbarNav" class="collapse navbar-collapse">
                  <ul id="globalNav-ul" class="navbar-nav" role="menubar">
                     <li id="globalNav-access" class="nav-item" role="presentation">
                        <span class="nav-link"> 
                        Access provided by: 
                        BMJ Group (Online access from BMA House)
                        </span>
                     </li>
                     <li id="globalNav-cmecpd" class="nav-item" role="menuitem">
                        <a class="nav-link" href="https://bestpractice.bmj.com/activity">CME / CPD</a>
                     </li>
                     <li id="globalNav-help" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" id="navbarDropdownMenuLink02" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> 
                        Help <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-help-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink02">
                           <span class="material-icons"></span>
                           <ul role="menu">
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></li>
                           </ul>
                        </div>
                     </li>
                     <li id="globalNav-account" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" id="navbarDropdownMenuLink01" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        <span class="material-icons"></span>&nbsp;
                        <span>stailor@bmj.com</span> 
                        <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-account-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink01">
                           <span class="material-icons"></span>
                           <ul class="list-group" role="menu">
                              <li class="dropdown-item">
                                 <form method="POST" action="https://bestpractice.bmj.com/logout">
                                    <input type="hidden" name="loggedIn" id="loggedIn" value="true">
                                    <button type="submit" value="Log out">
                                    Log out
                                    </button>
                                 </form>
                              </li>
                              <li class="dropdown-item"><a href="https://myaccount.bmj.com/myaccount/account/home-view.html?fwdUrl=https://bestpractice.bmj.com" target="_blank">My details</a></li>
                              <li hidden="hidden" class="dropdown-item"><a href="https://myaccount.bmj.com/myaccount/account/home-view.html#email-matrix-container?fwdUrl=https://bestpractice.bmj.com" target="_blank">My emails</a></li>
                           </ul>
                        </div>
                     </li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
         <div id="mainSearch" class="container">
            <div class="row">
               <div class="col-lg-7">
                  <div class="logo-img"><a href="https://bestpractice.bmj.com/"><span class="remove"><abbr title="British Medical Journal">BMJ</abbr> Best Practice</span></a></div>
               </div>
               <div class="col-lg-5">
                  <style type="text/css">
                     #searchBoxWrap .tt-open:before {content: "Recently viewed topics:"; }
                     #searchBoxWrap .tt-label-override:before,
                     #searchBoxWrap .tt-suggested:before {content: "Suggested topics:" !important; }
                  </style>
                  <form id="searchBoxForm" action="https://bestpractice.bmj.com/search" role="search" novalidate="novalidate">
                     <div class="input-group">
                        <div id="searchBoxWrap">
                           <label for="q" class="sr-only">Search</label>
                           <span class="twitter-typeahead" style="position: relative; display: inline-block;">
                              <input id="q" type="text" name="q" placeholder="Search conditions, symptoms..." value="" class="tt-input" autocomplete="off" spellcheck="false" dir="auto" style="position: relative; vertical-align: top;">
                              <pre aria-hidden="true" style="position: absolute; visibility: hidden; white-space: pre; font-family: sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
                              <div class="tt-menu" style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
                                 <div class="tt-dataset tt-dataset-0"></div>
                              </div>
                           </span>
                           <button id="mainSearchBtn" type="submit"><span class="material-icons"></span></button>
                        </div>
                     </div>
                  </form>
                  <script>
                     /*<![CDATA[*/
                     
                            <!-- These are required in completion, see BP-232 -->
                            var searchDefaultLanguageCode = "en-gb";
                            var regionName = "GB and ROW";
                            var regionAvailableLanguagesCodes = [{"id":"1","code":"en-gb","displayName":"English"},{"id":"3","code":"pt-br","displayName":"Portugu\u00EAs"},{"id":"5","code":"es-es","displayName":"Espa\u00F1ol"},{"id":"7","code":"ru-ru","displayName":"\u0420\u0443\u0441\u0441\u043A\u0438\u0439"}];
                            var availableLanguages = [];
                     
                            for (i = 0; i < regionAvailableLanguagesCodes.length; i++) {
                                availableLanguages.push(regionAvailableLanguagesCodes[i].code);
                            }
                     /*]]>*/
                  </script>
               </div>
            </div>
         </div>
         <nav id="mainNav" class="navbar navbar-toggleable-md" role="navigation">
            <div class="container">
               <div id="mainNavbarNav">
                  <ul class="navbar-nav" role="menubar">
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
      </header>
      <main id="tmp" class="container tmp treatment-table more-pops main-container" role="main">
         <script type="text/javascript">
            /*<![CDATA[*/ 
            var topicId = 151; 
            var langCode="en-gb"; 
            /*]]>*/
         </script>
         <div id="topicNav" class="container">
            <div class="lang">
               <ul role="menu">
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/151" class="active">English</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/pt-br/151">Português</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/es-es/151">Español</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/ru-ru/151">Русский</a></li>
               </ul>
            </div>
            <div id="topicMenuTopBg" style="height: 110px;"></div>
            <div id="topicMenuTopWrap" style="height: 110px;">
               <div id="topicMenuTop" style="height: 110px;">
                  <h1>Non-ST-elevation myocardial infarction</h1>
                  <div class="pdf-links-nav">
                     <div class="pdf">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/pdf/151.pdf" target="_blank">
                        <span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span>
                        </a>
                     </div>
                  </div>
                  <div id="mobileMenu" class="mUp">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="button">
                     <span><span class="material-icons"></span> Menu</span>
                     <span><span class="material-icons"></span> Close</span>
                     </a>
                  </div>
                  <ul id="menuLinks" role="menu">
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#smenu-0" aria-owns="menu-0">Overview <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#smenu-1" aria-owns="menu-1">Theory <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#smenu-2" aria-owns="menu-2">Diagnosis <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#smenu-3" aria-owns="menu-3">Management <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#smenu-4" aria-owns="menu-4">Follow up <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#smenu-5" aria-owns="menu-5">Resources <span class="material-icons"></span><span class="material-icons"></span></a></li>
                  </ul>
               </div>
            </div>
            <div id="topicMenuBottomWrap" style="height: 208px;">
               <nav id="topicMenuBottom" class="mUp" role="navigation" style="height: 208px;">
                  <ul id="menus" role="menubar">
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" class="parent"><span>Overview</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-0">
                          <li><a href="151_NSTEMI_overview_summary.html" id="Summary">Summary</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" class="parent"><span>Theory</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-1">
                          <li><a href="151_NSTEMI_theory_epidemiology.html" id="Epidemiology">Epidemiology</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/aetiology" id="Aetiology">Aetiology</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/case-history" id="Case history">Case history</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" class="parent"><span>Diagnosis</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-2">
                          <li><a href="151_NSTEMI_diagnosis_recommendations.html" id="Recommendations">Recommendations</a></li>
                          <li><a href="151_NSTEMI_diagnosis_hisotry_and_exam.html" id="History and exam">History and exam</a></li>
                          <li><a href="151_NSTEMI_diagnosis_investigations.html" id="Investigations">Investigations</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/differentials" id="Differentials">Differentials</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/criteria" id="Criteria">Criteria</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" class="parent"><span>Management</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-3">
                          <li><a href="151_NSTEMI_management_recommendations.html" id="Recommendations">Recommendations</a></li>
                           <li><a href="151_NSTEMI_management_treatment_algorithm.html" id="Treatment algorithm" class="active">Treatment algorithm</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/prevention" id="Prevention">Prevention</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/patient-discussions" id="Patient discussions">Patient discussions</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" class="parent"><span>Follow up</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-4">
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/monitoring" id="Monitoring">Monitoring</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/complications" id="Complications">Complications</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/prognosis" id="Prognosis">Prognosis</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" class="parent"><span>Resources</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-5">
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/guidelines" id="Guidelines">Guidelines</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/images-and-videos" id="Images and videos">Images and videos</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/references" id="References">References</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/patient-leaflets" id="Patient leaflets">Patient leaflets</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/calculators" id="Calculators">Calculators</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/151/evidence" id="Evidence">Evidence</a></li>
                        </ul>
                     </li>
                     <li class="mpdf"><a href="https://bestpractice.bmj.com/topics/en-gb/151/pdf/151.pdf" target="_blank"><span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span></a></li>
                  </ul>
               </nav>
            </div>
         </div>
         <h2 id="sr-content">Treatment algorithm</h2>
         <p class="w-75">Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">see disclaimer</a></p>
         <div class="card">
            <div class="card-block">
               <div class="container">
                  <div class="rowHead" id="acute">
                     <div class="col-md-12">
                        ACUTE
                     </div>
                  </div>
                  <div class="panel bg-line">
                     <div class="panel-heading">
                        <h3>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" id="patientGroup-0-0">
                           <span>acute presentation</span>
                           <span class="hidden-sm-down">
                           <span class="msg">VIEW ALL</span>
                           <span class="material-icons" role="button"><span></span><span></span></span>
                           </span>
                           </a>
                        </h3>
                     </div>
                     <!--/.panel-heading -->
                     <div class="panel-body">
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_0_0_0" aria-controls="panel_0_0_0" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">antiplatelet therapy</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_0" id="panel_0_0_0" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <h5>aspirin-tolerant</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_af8c930f-f3d3-4beb-9b1f-d11116cfedfc_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">aspirin</a><span>: </span><span>150-300 mg orally as a single dose, followed by 75 mg once daily thereafter</span>
                                    </p>
                                    <p class="and-or">-- AND --</p>
                                    <p>
                                       <a href="#drugDbPop_d7f98321-46b8-49f0-b09f-42f14c32e79e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">clopidogrel</a><span>: </span><span>300-600 mg orally as a loading dose, followed by 75 mg once daily</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="#drugDbPop_6efae9df-069f-459d-b2d1-5bd9a3d898a8_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ticagrelor</a><span>: </span><span>180 mg orally as loading dose, followed by 90 mg twice daily</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="#drugDbPop_135e965a-040e-4b04-886d-534856fc2537_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">prasugrel</a><span>: </span><span>60 mg orally as a loading dose, followed by 10 mg once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <h5>aspirin-intolerant</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_d7f98321-46b8-49f0-b09f-42f14c32e79e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">clopidogrel</a><span>: </span><span>300-600 mg orally as a loading dose, followed by 75 mg once daily</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="#drugDbPop_6efae9df-069f-459d-b2d1-5bd9a3d898a8_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ticagrelor</a><span>: </span><span>180 mg orally as loading dose, followed by 90 mg twice daily</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="#drugDbPop_135e965a-040e-4b04-886d-534856fc2537_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">prasugrel</a><span>: </span><span>60 mg orally as loading dose, followed by 10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 All patients should be given dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor. If the patient is intolerant of aspirin or it is otherwise contraindicated, a P2Y12 receptor inhibitor can be given alone, but two different P2Y12 receptor inhibitors should not be given together. Clopidogrel or ticagrelor are suitable for patients on either noninvasive or invasive strategies, while prasugrel is recommended only for patients on an invasive strategy since existing data come from patients treated by percutaneous interventions.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop64" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[64]</a> 
                                 <span class="citationText" aria-hidden="true">O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009 Aug 18;54(8):678-85.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19679245?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Aspirin should be given on clinical suspicion or diagnosis of acute coronary syndrome and continued indefinitely.
                                 <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                                 <span class="reference">
                                    <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_1" name="evidence-score-1" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#popuplink-ref-score_1" data-original-title="">
                                    Evidence A
                                    </a>
                                    <span class="esContent" aria-hidden="true">
                                       <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                                       Reduction in mortality: there is good-quality evidence that antiplatelet treatment (aspirin 75-325 mg/day) reduces the risk of death, MI, and stroke compared with placebo in people with unstable angina. The evidence suggests no added cardiovascular benefit, but possible added harm, from doses of aspirin &gt;325 mg daily.
                                    </span>
                                    <span class="esInfo" aria-hidden="true">
                                    Systematic reviews (SRs) or randomized controlled trials (RCTs) of &gt;200 participants.
                                    </span>
                                 </span>
                                 Healthcare personnel providing pre-hospital emergency services should give patients a single loading dose of aspirin as soon as possible to chest pain patients suspected of having acute coronary syndrome unless contraindicated or already taken by the patient.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop74" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[74]</a> 
                                 <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Unstable angina and NSTEMI: early management. Nov 2013 [internet publication].</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.nice.org.uk/guidance/CG94
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 High-dose aspirin is associated with an increased risk of bleeding when compared with low-dose aspirin and in the absence of improved outcomes.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 A loading dose of a P2Y12 receptor inhibitor is given as soon as possible on admission and then a maintenance dose is given for up to 12 months.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop115" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[115]</a> 
                                 <span class="citationText" aria-hidden="true">Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol. 2006 Oct 3;48(7):1339-45.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/48/7/1339
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17010792?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                                 <span class="reference">
                                    <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_7" name="evidence-score-7" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#popuplink-ref-score_7" data-original-title="">
                                    Evidence A
                                    </a>
                                    <span class="esContent" aria-hidden="true">
                                       <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                                       Prevention of MI: there is good-quality evidence that clopidogrel plus aspirin reduces the risk of death, MI, and stroke at 9 months in people with unstable angina. This combination has been associated with an increase in major bleeding, but not haemorrhagic stroke, compared with aspirin alone at 6 to 9 months.
                                    </span>
                                    <span class="esInfo" aria-hidden="true">
                                    Systematic reviews (SRs) or randomized controlled trials (RCTs) of &gt;200 participants.
                                    </span>
                                 </span>
                                 One trial showed that adding clopidogrel to aspirin therapy in acute myocardial infarction (MI) prevents 10 major vascular events per 1000 treated.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop116" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[116]</a> 
                                 <span class="citationText" aria-hidden="true">Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5;366(9497):1607-21.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/16271642?tool=bestpractice.com
                                 </span>
                                 </span>
                                 P2Y12 receptor inhibitors can reduce mortality and morbidity, but they may be associated with increased bleeding risk.
                                 <span class="reference">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop58" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[58]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Motovska Z, Kala P. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Clin Ther. 2008;30 Pt 2
                                       <rc-c2d-number data-rc-number=":2191-202">:2191-202</rc-c2d-number>
                                       .
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/19281914?tool=bestpractice.com
                                    </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop59" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[59]</a> 
                                 <span class="citationText" aria-hidden="true">Squizzato A, Bellesini M, Takeda A, et al. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Cochrane Database Syst Rev. 2017 Dec 14;(12):CD005158.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005158.pub4/full
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/29240976?tool=bestpractice.com
                                 </span>
                                 </span>
                                 Ticagrelor and prasugrel are newer P2Y12 agents, which trials have shown to have a faster onset of action and greater efficacy compared with clopidogrel, but with an increased risk of bleeding.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop60" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[60]</a> 
                                 <span class="citationText" aria-hidden="true">Mahaffey KW, Held C, Wojdyla DM, et al; PLATO Investigators. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014 Apr 22;63(15):1493-9.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/24561148?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop61" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[61]</a> 
                                 <span class="citationText" aria-hidden="true">Pollack CV Jr, Davoudi F, Diercks DB, et al; PLATO Investigators. Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clin Cardiol. 2017 Jun;40(6):390-8.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://onlinelibrary.wiley.com/doi/full/10.1002/clc.22733
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/28598510?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Note that P2Y12 receptor inhibitors should not be given if urgent coronary artery bypass graft (CABG) is anticipated or planned within 5-7 days, so it may be necessary to delay starting a P2Y12 receptor inhibitor until diagnostic angiography clarifies whether early CABG is indicated.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 For patients receiving chronic clopidogrel therapy prior to presentation, there is some evidence to suggest decreased periprocedural MI with clopidogrel reloading at the time of percutaneous coronary intervention.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Patti G, Pasceri V, Mangiacapra F, et al; ARMYDA-8 RELOAD-ACS Investigators. Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet Therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial). Am J Cardiol. 2013 Jul 15;112(2):162-8.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/23601577?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 There are variable responses to antiplatelet inhibition with clopidogrel based on loss-of-function alleles for the CYP219C enzyme, which is required to convert clopidogrel to its active drug metabolite. The presence of at least one loss-of-function mutation for CYP219C may be as high as 30% in some populations. In a single-centre retrospective study of clopidogrel resistance, it appeared that patients with clopidogrel resistance who remain on clopidogrel are at a fourfold increase for major adverse cardiovascular or cerebrovascular events compared with those placed on a different P2Y12 inhibitor.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop65" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[65]</a> 
                                 <span class="citationText" aria-hidden="true">Lee CR, Sriramoju VB, Cervantes A, et al. Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. Circ Genom Precis Med. 2018 Apr;11(4):e002069.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/29615454?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Conflicting data regarding interactions between proton-pump inhibitors and clopidogrel have resulted in broad warnings by regulatory agencies. There are weak data documenting decreased platelet assay responsiveness and worse outcomes in retrospective clinical studies of patients using clopidogrel and proton-pump inhibitors together. The results of the only large randomised trial appear to refute earlier observational data and found no increase in risk with co-administration of these agents. Proton-pump inhibitors are recommended for patients with a history of NSTEMI who also require triple therapy, particularly when there is a history of gastrointestinal bleeding. Clinical discretion is advised, as guidelines do not fully address this controversy.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop117" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[117]</a> 
                                 <span class="citationText" aria-hidden="true">O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19;374(9694):989-97.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19726078?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_0_0_1" aria-controls="panel_0_0_1" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">oxygen</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_1" id="panel_0_0_1" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 All patients require oxygen saturation measurement using pulse oximetry.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                                 &nbsp;Supplemental oxygen should be administered only to patients with an arterial oxygen saturation &lt;90%, respiratory distress, or other high-risk features for hypoxaemia.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop4" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[4]</a> 
                                 <span class="citationText" aria-hidden="true">Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://academic.oup.com/eurheartj/article/37/3/267/2466099
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/26320110?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Liberal use of oxygen is associated with increased mortality in patients with acute coronary syndrome.
                                 <span class="reference">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop53" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[53]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018 Apr 28;391(10131)
                                       <rc-c2d-number data-rc-number=":1693-705">:1693-705</rc-c2d-number>
                                       .
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/29726345?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_0_0_2" aria-controls="panel_0_0_2" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">glyceryl trinitrate ± morphine</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_2" id="panel_0_0_2" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_c02c41cd-c7ff-4f20-9785-17300f6bfb24_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">glyceryl trinitrate translingual</a><span>: </span><span>400-800 micrograms (1-2 sprays) every 5 minutes, maximum 3 doses</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_5b888bfe-ea34-483a-9dc6-cf3485e79333_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">glyceryl trinitrate</a><span>: </span><span>0.3 to 0.6 mg sublingually every 5 minutes, maximum 3 doses</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Secondary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_5b888bfe-ea34-483a-9dc6-cf3485e79333_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">glyceryl trinitrate</a><span>: </span><span>5 micrograms/min intravenously initially, increase by 5-20 micrograms/min increments every 3-5 minutes, maximum 200 micrograms/min</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Tertiary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_fe05c975-343c-41a6-8c4b-2b2ca714151b_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">morphine sulfate</a><span>: </span><span>2-5 mg intravenously every 5-30 minutes when required</span>
                                    </p>
                                    <p class="small-or">and</p>
                                    <p>
                                       <a href="#drugDbPop_5b888bfe-ea34-483a-9dc6-cf3485e79333_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">glyceryl trinitrate</a><span>: </span><span>5 micrograms/min intravenously initially, increase by 5-20 micrograms/min increments every 3-5 minutes, maximum 200 micrograms/min</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_fe05c975-343c-41a6-8c4b-2b2ca714151b_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">morphine sulfate</a><span>: </span><span>2-5 mg intravenously every 5-30 minutes when required</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Glyceryl trinitrate (GTN) is contraindicated if there is a history of recent phosphodiesterase-5 inhibitor use (e.g., sildenafil); it should not be given if systolic BP is &lt;90 mmHg or there is a concern about right ventricular infarct.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Intravenous GTN is indicated if 3 doses of sublingual GTN have not relieved the pain.
                                 <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                                 <span class="reference">
                                    <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_2" name="evidence-score-2" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#popuplink-ref-score_2" data-original-title="">
                                    Evidence C
                                    </a>
                                    <span class="esContent" aria-hidden="true">
                                       <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                                       Reduction in chest pain episodes: there is poor-quality evidence that glyceryl trinitrate reduces episodes of chest pain in people with unstable angina.
                                    </span>
                                    <span class="esInfo" aria-hidden="true">
                                    Poor quality observational (cohort) studies or methodologically flawed randomized controlled trials (RCTs) of &lt;200 participants. 
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Morphine should be added early if GTN is not sufficient. Morphine, in addition to its analgesic and anxiolytic properties, has haemodynamic effects that are potentially beneficial in unstable angina and NSTEMI.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Morphine causes vasodilation and may produce reductions in heart rate (through increased vagal tone) and systolic BP to further reduce myocardial oxygen demand.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                                 If GTN is not effective or is contraindicated, morphine can be given as an alternative in the absence of any contraindications. Limited data (largely observational studies) investigate morphine use for NSTEMI with evidence of potential safety concerns, thus it should be used with caution.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop68" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[68]</a> 
                                 <span class="citationText" aria-hidden="true">Meine TJ, Roe MT, Chen AY, et al; CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005 Jun;149(6):1043-9.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/15976786?tool=bestpractice.com
                                 </span>
                                 </span>
                                 One small, randomised, double-blind trial found that morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop69" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[69]</a> 
                                 <span class="citationText" aria-hidden="true">Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016 Jan 14;37(3):245-52.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://academic.oup.com/eurheartj/article/37/3/245/2467204
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/26491112?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">beta-blocker</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_d4b268c9-53e2-4caa-b5d4-36b5d1728141_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">metoprolol</a><span>: </span><span>50-100 mg orally (regular-release) twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_ed0b35d8-aa5b-479b-94e5-1ee8ca57ec47_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">atenolol</a><span>: </span><span>50-100 mg/day orally</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_0530d633-bf69-4255-9831-68b8e56fb430_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propranolol</a><span>: </span><span>180-320 mg/day orally (immediate-release) given in 3-4 divided doses</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Oral beta-blockers are indicated for all patients unless contraindicated.
                                 <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                                 <span class="reference">
                                    <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_3" name="evidence-score-3" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#popuplink-ref-score_3" data-original-title="">
                                    Evidence C
                                    </a>
                                    <span class="esContent" aria-hidden="true">
                                       <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                                       Reduction in mortality: there is poor-quality evidence that propranolol reduces mortality, MI, and requirement for CABG or percutaneous coronary interventions at 30 days compared with placebo in people with unstable angina who are taking optimal doses of nitrates and nifedipine.
                                    </span>
                                    <span class="esInfo" aria-hidden="true">
                                    Poor quality observational (cohort) studies or methodologically flawed randomized controlled trials (RCTs) of &lt;200 participants. 
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Treatment should begin within a few days of the event, if not initiated acutely, and should be continued indefinitely, especially in patients with reduced left ventricular function.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Contraindications to beta-blocker therapy include heart rate &lt;60 bpm, systolic BP &lt;100 mmHg, moderate or severe left ventricular failure, PR interval on the ECG &gt;0.24 seconds, second- or third-degree heart block, active asthma/reactive airways disease, severe COPD, right ventricular infarction, and cardiogenic shock.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop70" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[70]</a> 
                                 <span class="citationText" aria-hidden="true">American College of Cardiology Foundation, American Health Association, Agency for Healthcare Research and Quality, et al. Fact sheet: beta-blockers for acute myocardial infarction. Apr 2005 [internet publication].</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://archive.ahrq.gov/clinic/commitfact.htm
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop71" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[71]</a> 
                                 <span class="citationText" aria-hidden="true">American College of Cardiology Foundation, American Health Association, Agency for Healthcare Research and Quality, et al. Practice advisory: commitment to respond to COMMIT/CCS-2 trial beta blocker use for myocardial infarction (MI) within 24 hours of hospital arrival. Apr 2005 [internet publication].</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://archive.ahrq.gov/clinic/commitadvisory.htm
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Randomised trials with threatened or evolving myocardial infarction (MI) have shown lower rates of progression to MI with beta-blocker treatment.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop70" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[70]</a> 
                                 <span class="citationText" aria-hidden="true">American College of Cardiology Foundation, American Health Association, Agency for Healthcare Research and Quality, et al. Fact sheet: beta-blockers for acute myocardial infarction. Apr 2005 [internet publication].</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://archive.ahrq.gov/clinic/commitfact.htm
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop71" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[71]</a> 
                                 <span class="citationText" aria-hidden="true">American College of Cardiology Foundation, American Health Association, Agency for Healthcare Research and Quality, et al. Practice advisory: commitment to respond to COMMIT/CCS-2 trial beta blocker use for myocardial infarction (MI) within 24 hours of hospital arrival. Apr 2005 [internet publication].</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://archive.ahrq.gov/clinic/commitadvisory.htm
                                 </span>
                                 </span>
                                 Comparative studies between the various beta-blockers in the acute setting are lacking. However, beta-blockers without intrinsic sympathomimetic activity (e.g., metoprolol, propranolol, and atenolol) are preferred for initial management.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Selection of a long-term beta-blocker often depends on the clinician's familiarity with the agent. The goal resting heart rate is 50 to 60 bpm.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_0_0_4" aria-controls="panel_0_0_4" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">calcium-channel blocker</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_4" id="panel_0_0_4" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_7508539a-5d2a-4eab-ab36-fccb0194a2fe_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">diltiazem</a><span>: </span><span>30-90 mg orally (immediate-release) four times daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_b705ae48-b250-4f5e-af99-a9a1ab9c9dca_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">verapamil</a><span>: </span><span>80-120 mg orally (immediate-release) three times daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_28b33ba9-a303-4862-b6b7-e2f9b139d535_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amlodipine</a><span>: </span><span>5-10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Calcium-channel blockers can be given to patients with continuing or recurrent ischaemic symptoms after being given adequate nitrate and beta-blocker therapy, or those who cannot tolerate beta-blockers.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                                 Although they are often used, they are no more effective than control at reducing mortality or myocardial infarction rates in people with unstable angina.
                                 <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                                 <span class="reference">
                                    <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_4" name="evidence-score-4" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#popuplink-ref-score_4" data-original-title="">
                                    Evidence C
                                    </a>
                                    <span class="esContent" aria-hidden="true">
                                       <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                                       Reduction in mortality: calcium-channel blockers are no more effective than control at reducing mortality or MI rates in people with unstable angina. Short-acting dihydropyridine calcium-channel blockers (such as nifedipine) have been associated with increased mortality in people with coronary heart disease.
                                    </span>
                                    <span class="esInfo" aria-hidden="true">
                                    Poor quality observational (cohort) studies or methodologically flawed randomized controlled trials (RCTs) of &lt;200 participants. 
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Patients treated acutely with a calcium-channel blocker for acute angina do not need to continue these drugs, provided there is no recurrent angina on drug cessation or another indication for these drugs (i.e., hypertension). These drugs can be tapered after 24 hours at the discretion of the clinician.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Short-acting dihydropyridines (e.g., nifedipine) should be avoided in the absence of adequate beta-blocker therapy because they may be associated with adverse outcomes.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Verapamil or diltiazem should be avoided in severe left ventricular dysfunction.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                                 In the UK, use of calcium channel blockers as add-on therapy is not routine, unless beta-blockers not tolerated or contraindicated. 
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_0_0_5" aria-controls="panel_0_0_5" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">assess need for invasive or conservative approach</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_5" id="panel_0_0_5" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The latest guidelines recommend that high-risk patients routinely undergo early (12-24 hours) coronary angiography and angiographically directed revascularisation unless patients have serious comorbidities. However, since the release of these guidelines, an increasing amount of new data, systematic reviews, and expert opinion question the benefit of routine invasive versus selective invasive approaches, especially in low-risk patients; this is an evolving field in NSTEMI.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                                 <span class="citationText" aria-hidden="true">Damman P, van Geloven N, Wallentin L, et al. Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv. 2012 Feb;5(2):191-9.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/22361604?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop85" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[85]</a> 
                                 <span class="citationText" aria-hidden="true">Hoedemaker NP, Damman P, Woudstra P, et al; ICTUS Investigators. Early invasive versus selective strategy for non-ST-segment elevation acute coronary syndrome: the ICTUS trial. J Am Coll Cardiol. 2017 Apr 18;69(15):1883-93.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/69/15/1883
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/28408018?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop118" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[118]</a> 
                                 <span class="citationText" aria-hidden="true">Bolognese L. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes. Curr Med Res Opin. 2007 Jun;23(6):1217-26.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17559721?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop119" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[119]</a> 
                                 <span class="citationText" aria-hidden="true">Hernández AV, Westerhout CM, Steyerberg EW, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart. 2007 Apr;93(4):450-5.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1861476/
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17065179?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop120" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[120]</a> 
                                 <span class="citationText" aria-hidden="true">Damman P, Hirsch A, Windhausen F, et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial: a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010 Mar 2;55(9):858-64.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/55/9/858
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/20045278?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 An invasive approach is recommended if any of the following high-risk features are present:
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                                 [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                                 </a>
                                 <span class="ccaTitle" aria-hidden="true">How do routine and selective invasive strategies compare for the treatment of unstable angina and non-ST elevation myocardial infarction?</span>
                                 <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1452/full</span>
                                 <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                                 </span>
                                 &nbsp;recurrent angina or ischaemia at rest or with low-level activities despite intensive medical therapy; elevated cardiac biomarkers (troponin T or I); new or presumably new ST-segment depression; signs or symptoms of heart failure or new or worsening mitral regurgitation; high-risk findings from non-invasive testing; haemodynamic instability; sustained ventricular tachycardia; percutaneous coronary intervention within 6 months; prior coronary artery bypass graft; high-risk score (i.e., TIMI, GRACE); reduced left ventricular function (ejection fraction &lt;0.40).
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 A conservative approach may be appropriate in subsets of patients, especially those without high-risk features and with a low risk score. These include low-risk women 
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop86" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[86]</a> 
                                 <span class="citationText" aria-hidden="true">O'Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008 Jul 2;300(1):71-80.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/18594042?tool=bestpractice.com
                                 </span>
                                 </span>
                                 and older patients with comorbidities.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop121" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[121]</a> 
                                 <span class="citationText" aria-hidden="true">Alexander KP, Newby LK, Cannon CP, et al; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes. Circulation. 2007 May 15;115(19):2549-69.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.ahajournals.org/doi/full/10.1161/circulationaha.107.182615
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17502590?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="nested-collapse_0_0_6" aria-controls="nested-collapse_0_0_6" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 invasive approach planned                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">percutaneous coronary intervention</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_6" id="nested-collapse_0_0_6" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Angioplasty is coupled with placement of stents.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop90" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[90]</a> 
                                 <span class="citationText" aria-hidden="true">Levine GN, Bates ER, Blankenship JC, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. J Am Coll Cardiol. 2011 Dec 6;58(24):e44-122.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/58/24/e44
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/22070834?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Complications of percutaneous coronary intervention (PCI) include PCI-induced MI; coronary perforation, dissection, or rupture; cardiac tamponade; malignant arrhythmias; cholesterol emboli; and bleeding from the access site. At experienced high-volume sites, radial artery access is preferred due to decreased access site complications.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop91" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[91]</a> 
                                 <span class="citationText" aria-hidden="true">Vranckx P, Frigoli E, Rothenbühler M, et al; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Eur Heart J. 2017 Apr 7;38(14):1069-80.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://academic.oup.com/eurheartj/article/38/14/1069/3058512
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/28329389?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Contrast-induced nephropathy is a common and potentially serious complication, especially in patients with baseline impaired renal function.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop92" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[92]</a> 
                                 <span class="citationText" aria-hidden="true">McCullough PA, Adam A, Becker C, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006 Sep 18;98(6A):5-13K.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/16949375?tool=bestpractice.com
                                 </span>
                                 </span>
                                 Stent thromboses (early and late) are a catastrophic complication.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="nested-collapse_0_0_7" aria-controls="nested-collapse_0_0_7" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 invasive approach planned                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_7" id="nested-collapse_0_0_7" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>60 units/kg intravenous bolus initially, followed by 12 units/kg/hour infusion, adjust dose to target aPTT of 50-75 seconds</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>30 mg intravenous bolus initially, followed by 1 mg/kg subcutaneously every 12 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_d4ccd444-8501-447d-848f-bc97c03774ba_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a><span>: </span><span>120 units/kg subcutaneously every 12 hours, maximum 10,000 units twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_a4adb6a6-1e28-4057-9789-361aa3c914b8_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">fondaparinux</a><span>: </span><span>2.5 mg subcutaneously once daily</span>
                                    </p>
                                    <p class="small-or">and</p>
                                    <p>
                                       <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>50-60 units/kg intravenous bolus as a single dose during PCI</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation therapy can be subcutaneous low molecular weight heparin (LMWH) (e.g., enoxaparin), intravenous unfractionated heparin (UFH), or fondaparinux, irrespective of the initial treatment strategy, and therapy can be continued throughout hospitalisation or until the time of percutaneous coronary intervention (PCI).
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop122" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[122]</a> 
                                 <span class="citationText" aria-hidden="true">Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007 Oct 30;50(18):1742-51.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17964037?tool=bestpractice.com
                                 </span>
                                 </span>
                                 In the event that the patient will be treated medically, without plans for PCI, fondaparinux may be used alone. However, for patients undergoing PCI, UFH or bivalirudin should be added to avoid catheter thrombosis. Bivalirudin is to be used only in patients who are to be managed with an early invasive strategy.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop123" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[123]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015 Sep 10;373(11)
                                       <rc-c2d-number data-rc-number=":997-1009">:997-1009</rc-c2d-number>
                                       .
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26324049?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 UFH and LMWH are thrombin inhibitors.
                                 <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                                 <span class="reference">
                                    <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_5" name="evidence-score-5" href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#popuplink-ref-score_5" data-original-title="">
                                    Evidence A
                                    </a>
                                    <span class="esContent" aria-hidden="true">
                                       <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                                       Prevention of MI: there is good-quality evidence that low molecular weight heparin reduces MI compared with unfractionated heparin in people with unstable angina. The evidence found no difference between the two treatments for major bleeds.
                                    </span>
                                    <span class="esInfo" aria-hidden="true">
                                    Systematic reviews (SRs) or randomized controlled trials (RCTs) of &gt;200 participants.
                                    </span>
                                 </span>
                                 Like heparin, their mechanism of action involves binding to antithrombin III to increase its anticoagulant activity. 
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 UFH and LMWH are contraindicated in patients with major bleeding, history of adverse drug reaction, or heparin-induced thrombocytopenia.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Creatinine clearance should be assessed before administering enoxaparin or fondaparinux. Patients with severe renal impairment (creatinine clearance &lt;30 mL/minute) should be considered for UFH over enoxaparin, or a dose reduction may be required in these patients. Fondaparinux is contraindicated in patients with severe renal impairment.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="nested-collapse_0_0_8" aria-controls="nested-collapse_0_0_8" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 invasive approach planned                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">glycoprotein IIb/IIIa inhibitor</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_8" id="nested-collapse_0_0_8" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_e709dc51-c94e-4729-b5e1-53dfa70a4a15_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">eptifibatide</a><span>: </span><span>180 micrograms/kg intravenous bolus initially at time of percutaneous coronary intervention, followed by 2 micrograms/kg/min infusion for up to 18-24 hours and a second bolus of 180 micrograms/kg/dose 10 minutes after the initial bolus</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_f091b72f-2471-48f2-ab6e-ec8a6c63b87f_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">tirofiban</a><span>: </span><span>0.4 micrograms/kg/min intravenous infusion for 30 minutes, followed by 0.1 micrograms/kg/min</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Glycoprotein (GB) IIb/IIIa inhibitors block platelet binding of fibrinogen to the GP IIb/IIIa receptor.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                                 [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                                 </a>
                                 <span class="ccaTitle" aria-hidden="true">What are the effects of glycoprotein IIb/IIIa blockers as initial treatment in people with non-ST elevation acute coronary syndrome?</span>
                                 <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.469/full</span>
                                 <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                                 [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                                 </a>
                                 <span class="ccaTitle" aria-hidden="true">What are the effects of glycoprotein IIb/IIIa blockers during percutaneous coronary intervention?</span>
                                 <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.470/full</span>
                                 <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                                 </span>
                                 This is the final stage before platelet aggregation and the formation of thrombus.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Tirofiban
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop103" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[103]</a> 
                                 <span class="citationText" aria-hidden="true">Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001 Jun 21;344(25):1879-87.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.nejm.org/doi/full/10.1056/NEJM200106213442501
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11419424?tool=bestpractice.com
                                 </span>
                                 </span>
                                 or eptifibatide
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop124" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[124]</a> 
                                 <span class="citationText" aria-hidden="true">Brown DL, Fann CS, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol. 2001 Mar 1;87(5):537-41.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11230835?tool=bestpractice.com
                                 </span>
                                 </span>
                                 are preferred if GP IIb/IIIa inhibitor administration is planned; however, addition of a GP IIb/IIIa inhibitor is only recommended if there is evidence of a no-reflow or a thrombotic complication.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop118" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[118]</a> 
                                 <span class="citationText" aria-hidden="true">Bolognese L. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes. Curr Med Res Opin. 2007 Jun;23(6):1217-26.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17559721?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop119" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[119]</a> 
                                 <span class="citationText" aria-hidden="true">Hernández AV, Westerhout CM, Steyerberg EW, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart. 2007 Apr;93(4):450-5.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1861476/
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17065179?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop125" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[125]</a> 
                                 <span class="citationText" aria-hidden="true">Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006 Apr 5;295(13):1531-8.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://jamanetwork.com/journals/jama/fullarticle/202626
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/16533938?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="nested-collapse_0_0_9" aria-controls="nested-collapse_0_0_9" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 invasive approach not planned                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_0_0_9" id="nested-collapse_0_0_9" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>60 units/kg intravenous bolus initially, followed by 12-15 units/kg/hour infusion, adjust dose to target aPTT of 50-75 seconds</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>30 mg intravenous bolus initially, followed by 1 mg/kg subcutaneously every 12 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_d4ccd444-8501-447d-848f-bc97c03774ba_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a><span>: </span><span>120 units/kg subcutaneously every 12 hours, maximum 10,000 units twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_a4adb6a6-1e28-4057-9789-361aa3c914b8_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">fondaparinux</a><span>: </span><span>2.5 mg subcutaneously once daily for up to 8 days</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation therapy can be subcutaneous low molecular weight heparin (LMWH) (e.g., enoxaparin), or intravenous unfractionated heparin (UFH), or fondaparinux.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is contraindicated in patients with major bleeding, history of adverse drug reaction, or heparin-induced thrombocytopenia.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Creatinine clearance should be assessed before administering enoxaparin or fondaparinux. Patients with severe renal impairment (creatinine clearance &lt;30 mL/minute) should be considered for UFH over enoxaparin, or a dose reduction may be required in these patients. Fondaparinux is contraindicated in patients with severe renal impairment.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                     </div>
                     <!--/.panel-body -->
                  </div>
                  <!-- /.panel-group -->
               </div>
            </div>
         </div>
         <div class="card">
            <div class="card-block">
               <div class="container">
                  <div class="rowHead" id="ongoing">
                     <div class="col-md-12">
                        ONGOING
                     </div>
                  </div>
                  <div class="panel">
                     <div class="panel-heading">
                        <h3>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" id="patientGroup-1-0">
                           <span>post-stabilisation</span>
                           <span class="hidden-sm-down">
                           <span class="msg">VIEW ALL</span>
                           <span class="material-icons" role="button"><span></span><span></span></span>
                           </span>
                           </a>
                        </h3>
                     </div>
                     <!--/.panel-heading -->
                     <div class="panel-body">
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_1_0_0" aria-controls="panel_1_0_0" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">cardiac rehabilitation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_0" id="panel_1_0_0" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The aims of cardiac rehabilitation are to increase functional capacity; stop cigarette smoking; modify lipids and lipoproteins; decrease body weight and fat stores; reduce BP; improve psychosocial well-being; prevent progression and promote plaque stability; induce regression of underlying atherosclerosis; and restore and maintain optimal physical, psychological, emotional, social, and vocational functioning.
                                 <span class="reference">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop126" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[126]</a> 
                                    <span class="citationText" aria-hidden="true">Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease. Circulation. 2005 Jan 25;111(3):369-76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       https://www.ahajournals.org/doi/full/10.1161/01.cir
                                       <rc-c2d-number data-rc-number=".0000151788">.0000151788</rc-c2d-number>
                                       .08740.5c
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/15668354?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Cardiac rehabilitation should be started on discharge and after clearance by an outpatient physician. The basic prescription should include aerobic and weight-bearing exercise 4 to 5 times per week for &gt;30 minutes.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                                 [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                                 </a>
                                 <span class="ccaTitle" aria-hidden="true">What are the effects of exercise-based cardiac rehabilitation in people with coronary heart disease?</span>
                                 <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1187/full</span>
                                 <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                                 </span>
                                 There is a risk of triggering a recurrent myocardial infarction with physical activity. However, this is minimal and reduced by using a structured programme to minimise (and treat) this risk.
                                 <span class="reference">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop126" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[126]</a> 
                                    <span class="citationText" aria-hidden="true">Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease. Circulation. 2005 Jan 25;111(3):369-76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       https://www.ahajournals.org/doi/full/10.1161/01.cir
                                       <rc-c2d-number data-rc-number=".0000151788">.0000151788</rc-c2d-number>
                                       .08740.5c
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/15668354?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_1_0_1" aria-controls="panel_1_0_1" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">continue antiplatelet therapy</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_1" id="panel_1_0_1" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <h5>aspirin-tolerant</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_af8c930f-f3d3-4beb-9b1f-d11116cfedfc_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">aspirin</a><span>: </span><span>75 mg orally once daily</span>
                                    </p>
                                    <p class="and-or">-- AND --</p>
                                    <p>
                                       <a href="#drugDbPop_d7f98321-46b8-49f0-b09f-42f14c32e79e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">clopidogrel</a><span>: </span><span>75 mg orally once daily</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="#drugDbPop_6efae9df-069f-459d-b2d1-5bd9a3d898a8_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ticagrelor</a><span>: </span><span>90 mg orally twice daily</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="#drugDbPop_135e965a-040e-4b04-886d-534856fc2537_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">prasugrel</a><span>: </span><span>10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <h5>aspirin-intolerant</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_d7f98321-46b8-49f0-b09f-42f14c32e79e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">clopidogrel</a><span>: </span><span>75 mg orally once daily</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="#drugDbPop_6efae9df-069f-459d-b2d1-5bd9a3d898a8_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ticagrelor</a><span>: </span><span>90 mg orally twice daily</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="#drugDbPop_135e965a-040e-4b04-886d-534856fc2537_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">prasugrel</a><span>: </span><span>10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 In patients tolerant to aspirin, it should be continued indefinitely at a low dose. In addition, a P2Y12 receptor inhibitor should be continued for up to 12 months in patients treated medically (no stenting) or treated with a bare metal stent, and for at least 12 months for those patients treated with a drug-eluting stent.
                                 <span class="reference">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop66" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[66]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Bonaca MP, Bhatt DL, Cohen M, et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015 May 7;372(19)
                                       <rc-c2d-number data-rc-number=":1791-800">:1791-800</rc-c2d-number>
                                       .
                                    </span>
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.nejm.org/doi/full/10.1056/NEJMoa1500857
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25773268?tool=bestpractice.com
                                    </span>
                                 </span>
                                 Clopidogrel or ticagrelor are suitable for patients on either non-invasive or invasive strategies, while prasugrel is recommended only for patients on an invasive strategy since existing data comes from patients treated by percutaneous interventions.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop64" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[64]</a> 
                                 <span class="citationText" aria-hidden="true">O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009 Aug 18;54(8):678-85.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19679245?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 In patients intolerant of aspirin, or if it is otherwise contraindicated, a P2Y12 receptor inhibitor can be given alone, in which case it too should be continued indefinitely. Two different P2Y12 receptor inhibitors should not be given together.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 There are variable responses to antiplatelet inhibition with clopidogrel based on loss-of-function alleles for the CYP219C enzyme, which is required to convert clopidogrel to its active drug metabolite. The presence of at least one loss-of-function mutation for CYP219C may be as high as 30% in some populations. In a single-centre retrospective study of clopidogrel, resistance it appeared that patients with clopidogrel resistance who remain on clopidogrel are at a fourfold increase for major adverse cardiovascular or cerebrovascular events compared with those placed on a different P2Y12 inhibitor.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop65" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[65]</a> 
                                 <span class="citationText" aria-hidden="true">Lee CR, Sriramoju VB, Cervantes A, et al. Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. Circ Genom Precis Med. 2018 Apr;11(4):e002069.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/29615454?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_1_0_2" aria-controls="panel_1_0_2" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">continue beta-blocker</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_2" id="panel_1_0_2" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_d4b268c9-53e2-4caa-b5d4-36b5d1728141_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">metoprolol</a><span>: </span><span>25-200 mg orally (extended-release) once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_09fb6bfc-ec5f-49e2-9858-d7c7d0ab44f4_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">bisoprolol</a><span>: </span><span>1.25 to 10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_7a2f8cf6-5b94-4fc8-b62d-07d6cfc8444c_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">carvedilol</a><span>: </span><span>12.5 mg orally twice daily for 2 days, followed by 25 mg twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Oral beta-blockers should be continued indefinitely, especially in patients with reduced left ventricular function.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Cardioselective beta-blockers are preferred in the initial management of NSTEMI, but guidelines recommend metoprolol, bisoprolol, or carvedilol for post-NSTEMI management in patients with stabilised heart failure and reduced systolic function.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/64/24/e139
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25260718?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_1_0_3" aria-controls="panel_1_0_3" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">statin</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_3" id="panel_1_0_3" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <h5>high-intensity statin</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_a9253e3b-a9bc-4345-a719-c64958ba302f_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">atorvastatin</a><span>: </span><span>40-80 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <h5>high-intensity statin</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_39bf6ee7-1eea-4b0c-b988-6c1ac8363c5b_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rosuvastatin</a><span>: </span><span>20-40 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Secondary options</h4>
                                 <h5>moderate-intensity statin</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_a9253e3b-a9bc-4345-a719-c64958ba302f_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">atorvastatin</a><span>: </span><span>10-20 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <h5>moderate-intensity statin</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_39bf6ee7-1eea-4b0c-b988-6c1ac8363c5b_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rosuvastatin</a><span>: </span><span>5-10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <h5>moderate-intensity statin</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_b0b6203f-1a1c-4866-8ceb-5d45698dc127_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">lovastatin</a><span>: </span><span>40 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <h5>moderate-intensity statin</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_5ee04ad9-fbae-4a27-81b9-4abecfb054ce_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">fluvastatin</a><span>: </span><span>40 mg orally (immediate-release) twice daily; 80 mg orally (extended-release) once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <h5>moderate-intensity statin</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_8441419c-d367-42e4-9e9d-6caeeaf04af1_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">simvastatin</a><span>: </span><span>20-40 mg orally once daily</span>
                                    </p>
                                    <span class="reference">
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop-more0" data-trigger="click focus" data-toggle="popover" class="morePop" data-original-title="" title="">More</a>
                                       <span class="popTitle" aria-hidden="true">
                                       simvastatin	
                                       </span>
                                       <span class="popText" aria-hidden="true">
                                          <p class="w-75">
                                             <!-- col-md-9 -->
                                             Doses higher than 40 mg/day are not recommended due to the increased risk of myopathy.
                                          </p>
                                       </span>
                                    </span>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <h5>moderate-intensity statin</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_82f7726d-4db0-4c64-bf35-90165e9b8be7_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">pravastatin</a><span>: </span><span>40-80 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <h5>moderate-intensity statin</h5>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_c49d2b6b-d641-4183-8121-8243859d1c20_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">pitavastatin</a><span>: </span><span>2-4 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Statin therapy should be given before hospital discharge to all patients with acute coronary syndrome.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop127" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[127]</a> 
                                 <span class="citationText" aria-hidden="true">Colivicchi F, Tubaro M, Mocini D, et al. Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. Curr Med Res Opin. 2010 Jun;26(6):1277-84.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/20367555?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 All patients with NSTEMI should receive a high-intensity statin (moderate intensity if not candidate for high-intensity statin) regardless of cholesterol levels, and if there are no contraindications.
                                 <span class="reference">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop96" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[96]</a> 
                                    <span class="citationText" aria-hidden="true">Stone NJ, Robinson J, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       https://www.ahajournals.org/doi/full/10.1161/01.cir
                                       <rc-c2d-number data-rc-number=".0000437738">.0000437738</rc-c2d-number>
                                       .63853.7a
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24222016?tool=bestpractice.com
                                    </span>
                                 </span>
                                 A high-intensity statin is defined as a daily dose that lowers low-density lipoprotein cholesterol (LDL-C) by approximately &gt;50%, while a moderate-intensity statin daily dose lowers LDL-C by approximately 30% to 50%.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Statin therapy is particularly important in patients who have hyperlipidaemia, diabetes, prior myocardial infarction, or coronary artery disease. Statins inhibit the rate-limiting step in cholesterol synthesis. They may also reduce vascular inflammation, improve endothelial function, and decrease thrombus formation in addition to lowering LDL.
                                 <span class="reference">
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop21" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[21]</a> 
                                    <span class="citationText" aria-hidden="true">Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1524-34.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       https://www.ahajournals.org/doi/full/10.1161/01.atv
                                       <rc-c2d-number data-rc-number=".0000032033">.0000032033</rc-c2d-number>
                                       .39301.6a
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/12377727?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Patients should be monitored for jaundice, malaise, fatigue, and lethargy.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop128" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[128]</a> 
                                 <span class="citationText" aria-hidden="true">McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006 Apr 17;97(8A):89-94C.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/16581336?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Fractionated bilirubin should be used rather than alanine aminotransferase (ALT) or aspartate transaminase (AST) to detect liver dysfunction. If evidence of liver injury is found, the statin should be stopped. If ALT or AST exceeds 3 times the upper limit of normal, the levels can be repeated but there is no need to stop the statin.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop128" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[128]</a> 
                                 <span class="citationText" aria-hidden="true">McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006 Apr 17;97(8A):89-94C.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/16581336?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_1_0_4" aria-controls="panel_1_0_4" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">ezetimibe added to statin therapy</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_4" id="panel_1_0_4" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_1c3d50e5-809a-4505-aabf-bcb1d8479bb9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ezetimibe</a><span>: </span><span>10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The addition of ezetimibe to the statin regimen may also be considered to achieve lower low-density lipoprotein targets.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop20" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[20]</a> 
                                 <span class="citationText" aria-hidden="true">Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.nejm.org/doi/full/10.1056/NEJMoa1410489
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/26039521?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop99" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[99]</a> 
                                 <span class="citationText" aria-hidden="true">Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicentre randomized controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015 Aug 4;66(5):495-507.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/26227186?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_1_0_5" aria-controls="panel_1_0_5" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">PCSK-9 inhibitor</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_5" id="panel_1_0_5" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_442f0cc1-8d1c-4ea8-9e46-fab2e6e31afe_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">alirocumab</a><span>: </span><span>75-150 mg subcutaneously once every two weeks, or 300 mg subcutaneously once monthly</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_556ef3d9-253f-4f5a-be0c-868504ef6ee1_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">evolocumab</a><span>: </span><span>140 mg subcutaneously once every two weeks, or 420 mg subcutaneously once monthly</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The addition of alirocumab and evolocumab to maximally tolerated statin therapy may also be considered for patients who require additional low-density lipoprotein (LDL) lowering (&lt;50% reduction in LDL-C; may also consider if LDL-C ≥2.59 mmol/L [≥100 mg/dL]).
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop100" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[100]</a> 
                                 <span class="citationText" aria-hidden="true">Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713-22.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/28304224?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                 <span class="citationText" aria-hidden="true">Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 Jul 5;68(1):92-125.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.onlinejacc.org/content/68/1/92
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/27046161?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Alirocumab is approved for use as adjunct therapy to diet and maximally tolerated statin therapy for adult patients with heterozygous familial hypercholesterolaemia, or with clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Evolocumab is approved as an adjunct to diet and other lipid-lowering therapies (e.g., statins, ezetimibe) in patients with primary hyperlipidaemia (including heterozygous hypercholesterolaemia) and homozygous familial hypercholesterolaemia to reduce LDL. It is now also approved to reduce the risk of myocardial infarction in patients with established cardiovascular disease, and may be used for this indication without adjunctive diet and lipid-lowering therapies.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Evolocumab and alirocumab may also be used as an alternative to statins if they are contraindicated or the patient is intolerant of statins.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_1_0_6" aria-controls="panel_1_0_6" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">ACE inhibitor or angiotensin-II receptor antagonist</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_6" id="panel_1_0_6" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_681c45fe-039f-43ad-8fc8-56a3d643bf07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enalapril</a><span>: </span><span>2.5 mg orally once daily for 48 hours, increase gradually to 10 mg twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_01d7c659-f00d-41e9-bf6d-e83106c22c18_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">lisinopril</a><span>: </span><span>5 mg orally once daily for 48 hours, followed by 5-10 mg once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_9944def2-bd4b-49c4-9727-dcef3f46258e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">captopril</a><span>: </span><span>6.25 mg orally three times daily starting on day 3 post-MI, increase gradually to 50 mg three times daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Secondary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_02650099-2fd8-45cc-a14a-bafddd531269_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">valsartan</a><span>: </span><span>20 mg orally twice daily initially, increase gradually to 160 mg twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_dc535bd4-15b3-493b-9335-e82ce869eb21_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">losartan</a><span>: </span><span>50 mg orally once daily initially, increase gradually to 100 mg once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_ed971b3b-5fd6-4117-b01a-fad815e03325_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">candesartan</a><span>: </span><span>4 mg orally once daily initially, increase gradually to 32 mg once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Angiotensin-converting enzyme (ACE) inhibitors should be used in all patients with left ventricle systolic dysfunction (ejection fraction &lt;40%), heart failure, hypertension, diabetes, stable chronic kidney disease, or other high-risk features, such as ongoing ischaemia with worsening heart failure, S3 gallop, new or worsening mitral regurgitation, or haemodynamic instability, without overt cardiogenic shock.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Angiotensin-II receptor antagonists may be used in cases of intolerance to ACE inhibitors.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop129" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[129]</a> 
                                 <span class="citationText" aria-hidden="true">Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002 Sep 7;360(9335):752-60.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/12241832?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 ACE inhibitors or angiotensin-II receptor antagonists may be started 24 hours post myocardial infarction.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Goal BP is at least &lt;140/90 mmHg (including patients with chronic kidney disease or diabetes).
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop105" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[105]</a> 
                                 <span class="citationText" aria-hidden="true">James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://jamanetwork.com/journals/jama/fullarticle/1791497
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/24352797?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_1_0_7" aria-controls="panel_1_0_7" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">aldosterone antagonist</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_7" id="panel_1_0_7" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_afe5b4af-9344-4525-9fee-30aa50683d72_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">eplerenone</a><span>: </span><span>25 mg orally once daily initially, increase gradually to 50 mg once daily within 4 weeks</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_b27260f8-9327-4426-a7d1-9a65af0038a2_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">spironolactone</a><span>: </span><span>12.5 to 25 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Aldosterone antagonists (e.g., eplerenone, spironolactone) should be used in all patients with left ventricular dysfunction (ejection fraction ≤40%), a history of diabetes mellitus, or evidence of congestive heart failure (S3 gallop, rales). They should be started in patients receiving target doses of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor antagonists. Aldosterone blockade should not be used in patients with serum creatinine &gt;221 micromol/L (2.5 mg/dL) in men or &gt;177 micromol/L (2.0 mg/dL) in women, as well as in patients with hyperkalaemia (potassium &gt;5.0 mmol/L [5.0mEq/L]).
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop108" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[108]</a> 
                                 <span class="citationText" aria-hidden="true">Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309-21.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.nejm.org/doi/full/10.1056/NEJMoa030207
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/12668699?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" role="tab header" id="tab_1_0_8" aria-controls="panel_1_0_8" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_8" id="panel_1_0_8" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>consult specialist for guidance on dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>consult specialist for guidance on dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>consult specialist for guidance on dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Most patients do not need to continue anticoagulation after hospitalisation. A subset of patients who are high risk for a repeat thrombotic event may be put on chronic oral anticoagulation.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Rivaroxaban can be given to patients who have experienced an acute coronary syndrome at the discretion of the physician. Data from the ATLAS ACS 2-TIMI 51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin with/without Thienopyridine Therapy in Subjects with Acute Coronary Syndrome 2-Thrombolysis in Myocardial Infarction 51) indicated that low doses of rivaroxaban (i.e., 5 mg/day) reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke in addition to aspirin and clopidogrel. There is an increased risk of non-fatal bleeding that was observed in these trials.
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop111" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[111]</a> 
                                 <span class="citationText" aria-hidden="true">Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 5;366(1):9-19.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.nejm.org/doi/10.1056/NEJMoa1112277
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/22077192?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#referencePop112" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[112]</a> 
                                 <span class="citationText" aria-hidden="true">Mega JL, Braunwald E, Wiviott SD, et al. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). Am J Cardiol. 2013 Aug 15;112(4):472-8.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/23711804?tool=bestpractice.com
                                 </span>
                                 </span>
                                 It has been approved in some countries, although not in the US.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Patients with prior history of stroke/transient ischaemic attack, age older than 75 years, or &lt;60 kg body weight should not be started on rivaroxaban for this indication.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                     </div>
                     <!--/.panel-body -->
                  </div>
                  <!-- /.panel-group -->
               </div>
            </div>
         </div>
         <div class="card-block disclaimer">
            <p><span>Use of this content is subject to our <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">disclaimer</a> </span></p>
         </div>
         <script type="text/javascript">//<![CDATA[
            var drugDatabases = ["AHFS","BNF","BNFC","MARTINDALE","MICROMEDEX"];
            var drugMappings = {"442f0cc1-8d1c-4ea8-9e46-fab2e6e31afe":{"AHFS":"316009","BNF":"179798840","MARTINDALE":"29267-q"},"1c3d50e5-809a-4505-aabf-bcb1d8479bb9":{"BNFC":"619681801","AHFS":"302039","BNF":"619681801","MARTINDALE":"20694-d"},"556ef3d9-253f-4f5a-be0c-868504ef6ee1":{"BNFC":"931612348","AHFS":"316010","BNF":"931612348","MARTINDALE":"29414-h"},"d4ccd444-8501-447d-848f-bc97c03774ba":{"BNFC":"694891763","AHFS":"396006","BNF":"694891763","MARTINDALE":"14676-j"},"ed0b35d8-aa5b-479b-94e5-1ee8ca57ec47":{"BNFC":"811991159","AHFS":"384031","BNF":"811991159","MARTINDALE":"6304-s"},"135e965a-040e-4b04-886d-534856fc2537":{"AHFS":"309019","BNF":"550565517","MARTINDALE":"22133-g"},"39bf6ee7-1eea-4b0c-b988-6c1ac8363c5b":{"BNFC":"877590912","AHFS":"303040","BNF":"877590912","MARTINDALE":"20717-j"},"afe5b4af-9344-4525-9fee-30aa50683d72":{"AHFS":"302037","BNF":"845539498","MARTINDALE":"19998-m"},"ed971b3b-5fd6-4117-b01a-fad815e03325":{"BNFC":"790958181","AHFS":"302015","BNF":"790958181","MARTINDALE":"17153-e"},"b27260f8-9327-4426-a7d1-9a65af0038a2":{"BNFC":"213718345","AHFS":"382627","BNF":"213718345","MARTINDALE":"2355-e"},"7a2f8cf6-5b94-4fc8-b62d-07d6cfc8444c":{"BNFC":"563610075","AHFS":"397042","BNF":"563610075","MARTINDALE":"18917-n"},"1f043ef5-6686-4b38-a018-9dea67de1e36":{"BNFC":"107604022","AHFS":"382277","BNF":"107604022","MARTINDALE":"21515-l"},"0530d633-bf69-4255-9831-68b8e56fb430":{"BNFC":"202997782","AHFS":"382607","BNF":"202997782","MARTINDALE":"6301-g"},"d4b268c9-53e2-4caa-b5d4-36b5d1728141":{"BNFC":"671210145","AHFS":"382864","BNF":"671210145","MARTINDALE":"14830-p"},"28b33ba9-a303-4862-b6b7-e2f9b139d535":{"BNFC":"109201061","AHFS":"392044","BNF":"109201061","MARTINDALE":"18613-p"},"c49d2b6b-d641-4183-8121-8243859d1c20":{"AHFS":"311003","MARTINDALE":"20212-l"},"e709dc51-c94e-4729-b5e1-53dfa70a4a15":{"AHFS":"399009","BNF":"137641371","MARTINDALE":"15030-q"},"9944def2-bd4b-49c4-9727-dcef3f46258e":{"BNFC":"934086624","AHFS":"382823","BNF":"934086624","MARTINDALE":"856-c"},"681c45fe-039f-43ad-8fc8-56a3d643bf07":{"BNFC":"362871953","AHFS":"386022","BNF":"362871953","MARTINDALE":"17599-a"},"a9253e3b-a9bc-4345-a719-c64958ba302f":{"BNFC":"138735514","AHFS":"300045","BNF":"138735514","MARTINDALE":"14543-n"},"b705ae48-b250-4f5e-af99-a9a1ab9c9dca":{"BNFC":"111880283","AHFS":"384030","BNF":"111880283","MARTINDALE":"7794-v"},"dc535bd4-15b3-493b-9335-e82ce869eb21":{"BNFC":"958956352","AHFS":"395008","BNF":"958956352","MARTINDALE":"11145-s"},"b0b6203f-1a1c-4866-8ceb-5d45698dc127":{"AHFS":"388006","MARTINDALE":"16894-k"},"02650099-2fd8-45cc-a14a-bafddd531269":{"BNFC":"579351575","AHFS":"397015","BNF":"579351575","MARTINDALE":"17122-b"},"4866ce04-4d68-4b50-83f4-66283ea52c07":{"BNFC":"347445885","AHFS":"382826","BNF":"347445885","MARTINDALE":"11401-s"},"82f7726d-4db0-4c64-bf35-90165e9b8be7":{"BNFC":"554942047","AHFS":"392025","BNF":"554942047","MARTINDALE":"3758-z"},"6efae9df-069f-459d-b2d1-5bd9a3d898a8":{"AHFS":"312030","BNF":"860084761","MARTINDALE":"24808-m"},"5ee04ad9-fbae-4a27-81b9-4abecfb054ce":{"BNFC":"277471025","AHFS":"394010","BNF":"277471025","MARTINDALE":"5928-w"},"0f8c4ada-cd84-4c04-8860-01a81e07c1f9":{"AHFS":"312005","BNF":"758974083","MARTINDALE":"22005-r"},"fe05c975-343c-41a6-8c4b-2b2ca714151b":{"BNFC":"761904314","AHFS":"382133","BNF":"761904314","MARTINDALE":"6239-c"},"5b888bfe-ea34-483a-9dc6-cf3485e79333":{"BNFC":"491182041","AHFS":"382346","BNF":"491182041","MARTINDALE":"9237-z"},"3984222a-c42a-4f8a-bff1-f99645ade85d":{"BNFC":"190424995","AHFS":"393016","BNF":"190424995","MARTINDALE":"13424-s"},"f091b72f-2471-48f2-ab6e-ec8a6c63b87f":{"AHFS":"399039","BNF":"377992242","MARTINDALE":"19429-c"},"8441419c-d367-42e4-9e9d-6caeeaf04af1":{"BNFC":"413004542","AHFS":"392030","BNF":"413004542","MARTINDALE":"2452-l"},"7508539a-5d2a-4eab-ab36-fccb0194a2fe":{"BNFC":"873608533","AHFS":"384027","BNF":"873608533","MARTINDALE":"9225-e"},"aff9d94e-1579-4f56-acb7-73775d12d818":{"AHFS":"313017","BNF":"379487049","MARTINDALE":"24489-b"},"d7f98321-46b8-49f0-b09f-42f14c32e79e":{"AHFS":"301059","BNF":"255959538","MARTINDALE":"21688-w"},"01d7c659-f00d-41e9-bf6d-e83106c22c18":{"BNFC":"437242180","AHFS":"392051","BNF":"437242180","MARTINDALE":"16878-k"},"af8c930f-f3d3-4beb-9b1f-d11116cfedfc":{"BNFC":"456850132","AHFS":"382878","BNF":"456850132","MARTINDALE":"2601-s"},"09fb6bfc-ec5f-49e2-9858-d7c7d0ab44f4":{"AHFS":"393024","BNF":"281805035","MARTINDALE":"18615-w"},"a4adb6a6-1e28-4057-9789-361aa3c914b8":{"AHFS":"302012","BNF":"724890658","MARTINDALE":"20172-x"},"c02c41cd-c7ff-4f20-9785-17300f6bfb24":{"BNFC":"491182041","AHFS":"382346","BNF":"491182041","MARTINDALE":"9237-z"}};
            //]]>
         </script>
      </main>
      <script type="text/javascript" id="">(function(){var f=google_tag_manager["GTM-K3TZ3JV"].macro(4),b=google_tag_manager["GTM-K3TZ3JV"].macro(5),a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};f?"true"!=b&&("justLoggedIn"==b?a("loggedIn","true",2):a("loggedIn","justLoggedIn",2)):a("loggedIn","false",2)})();</script><script type="text/javascript" id="">var meta=document.createElement("meta");meta.name="msvalidate.01";meta.content="76FD53F39FDFB050A93D7925608BA016";document.getElementsByTagName("head")[0].appendChild(meta);</script>
      <!-- set the messages country code variable from region to be used from i18 plugin. Setting here so it's available in all pages -->
      <script>
         /*<![CDATA[*/
         
         var messagesCountryCode = "en_GB";
         /*]]>*/
           
      </script>
      <aside id="panel-nhs" class="card-block">
         <div id="access" class="col-sm-6">
            <div class="row">
               <div class="col-md-6">
                  <p>Access provided by:</p>
               </div>
               <div class="col-md-6">
                  <img src="../images/bmj-logo.png" alt="BMJ Group (Online access from BMA House)">
               </div>
            </div>
         </div>
      </aside>
      <footer id="footer">
         <div class="container">
            <div class="row">
               <nav class="col-md-9" role="navigation">
                  <div class="row">
                     <dl class="col-md-4" role="menu">
                        <dt>Browse</dt>
                        <dd><a href="https://bestpractice.bmj.com/">Home</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/recent-updates">Recent updates</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/specialties">Specialties</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/calculators">Calculators</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/patient-leaflets">Patient leaflets</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/procedural-videos">Procedural videos</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/evidence">Evidence</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/drugs">Drugs</a></dd>
                     </dl>
                     <!-- logged-in individual or institutional user -->
                     <dl class="col-md-4" role="menu">
                        <dt>Services</dt>
                        <dd id="footerLogout">
                           <form method="POST" action="https://bestpractice.bmj.com/logout" role="menuitem">
                              <input type="hidden" name="loggedIn" id="loggedIn" value="true">
                              <button type="submit" value="Log out">Log out</button>
                           </form>
                        </dd>
                        <dd>                        
                           <a href="https://myaccount.bmj.com/myaccount/account/home-view.html?fwdUrl=https://bestpractice.bmj.com" target="_blank">
                           My details
                           </a>  
                        </dd>
                        <dd hidden="hidden">           
                           <a href="https://myaccount.bmj.com/myaccount/account/home-view.html#email-matrix-container?fwdUrl=https://bestpractice.bmj.com" target="_blank">
                           My emails
                           </a>  
                        </dd>
                        <dd><a href="https://bestpractice.bmj.com/activity">CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/getting-started/">Getting started</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/faq/">FAQs</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/">About CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/">About us</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/app/">Mobile app</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/contact-us/">Contact us</a></dd>
                        <dd>
                           <a href="https://myaccount.bmj.com/myaccount/registration.html?regService=bestpractice-email-alert&amp;fwdUrl=https://bestpractice.bmj.com">
                           Sign up for email alerts
                           </a>
                        </dd>
                     </dl>
                     <!-- unknown user -->
                     <!--institutional user not logged in-->
                     <dl class="col-md-4" role="menu">
                        <dt>Legal</dt>
                        <dd><a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">Disclaimer</a></dd>
                        <dd><a href="https://www.bmj.com/company/legal-information/" target="_blank">Terms and conditions</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/" target="_blank">Privacy notice</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">Cookie policy</a></dd>
                     </dl>
                  </div>
                  <!-- row -->
               </nav>
               <div class="col-md-3">
                  <ul>
                     <li><a target="_blank" href="https://www.facebook.com/BMJBestPractice"><img alt="Facebook Logo" title="Facebook" src="../images/facebook-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://twitter.com/BMJBestPractice"><img alt="Twiter Logo" title="Twitter" src="../images/twitter-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.linkedin.com/showcase/15218227/"><img alt="LinkedIn Logo" title="LinkedIn" src="../images/linkedIn_logo_circle.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.youtube.com/channel/UCt72GZ0cPXpk4EzgFhdWYdQ"><img alt="Youtube Logo" title="YouTube" src="../images/youtube-64.png" width="60" height="60"></a></li>
                  </ul>
                  <p class="copyright mt-3"><small>© BMJ Publishing Group 2018</small></p>
                  <p class="issn">
                     <small>
                        ISSN
                        <rc-c2d-number data-rc-number=" 2515-9615"> 2515-9615</rc-c2d-number>
                     </small>
                  </p>
               </div>
            </div>
            <!-- row -->  
         </div>
         <!-- container -->    
      </footer>
      <div class="container modal-registration-form" aria-hidden="true">
         <div id="feedbackContainer" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-header">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Help us improve <abbr>BMJ</abbr> Best Practice</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                        <div class="col-md-12">
                           <p>Please complete all fields.</p>
                        </div>
                     </div>
                  </div>
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <form id="feedbackForm" action="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#" novalidate="novalidate">
                              <div class="row">
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackName">Name</label> 
                                       <input id="feedbackName" class="form-control" name="feedbackName" type="text">
                                    </div>
                                 </div>
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackEmail">Email</label> 
                                       <input id="feedbackEmail" class="form-control" name="feedbackEmail" type="email" value="stailor@bmj.com">
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <h2 id="feedbackPageTitle" class="h3">Page: Non-ST-elevation myocardial infarction - Treatment algorithm | BMJ Best Practice</h2>
                                 </div>
                              </div>
                              <input id="feedbackPage" name="feedbackPage" type="hidden" value="Non-ST-elevation myocardial infarction - Treatment algorithm | BMJ Best Practice">
                              <div class="row">
                                 <div class="col-md-4">
                                    <p>I have some feedback on:</p>
                                    <fieldset class="form-group" role="radiogroup">
                                       <legend>Feedback on: </legend>
                                       <label for="feedOn01"><input id="feedOn01" type="radio" name="feedbackOn" value="This page" checked="checked">&nbsp;This page</label>
                                       <label for="feedOn02"><input id="feedOn02" type="radio" name="feedbackOn" value="This website">&nbsp;The website in general</label>
                                       <label for="feedOn03"><input id="feedOn03" type="radio" name="feedbackOn" value="Something else">&nbsp;Something else</label>
                                    </fieldset>
                                 </div>
                                 <div class="col-md-8">
                                    <div class="form-group floating-label textarea">
                                       <label for="feedbackContent">I have some feedback on:</label>
                                       <textarea id="feedbackContent" name="feedbackContent"></textarea>
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <p>We will respond to all feedback.</p>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <button id="feedbackSubmit" type="submit" class="btn btn-secondary btn-lg">
                                    <span id="spinner2" class="progress-circular-inner progress-circular-left"></span>
                                    <span id="btnText2">Submit Feedback</span>
                                    </button>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-12">
                                    <p>For any urgent enquiries please contact our customer services team who are ready to help with any problems.</p>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-3">
                                    <p>
                                       <b>Phone:</b> 
                                       <rc-c2d-number data-rc-number="+44 (0) 207 111 1105">+44 (0) 207 111 1105</rc-c2d-number>
                                    </p>
                                 </div>
                                 <div class="col-md-3">
                                    <p><b>Email: </b> <a href="mailto:support@bmj.com">support@bmj.com</a></p>
                                 </div>
                              </div>
                           </form>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedbackSuccess" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackConfirmedLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Thank you</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                     </div>
                     <div class="row">
                        <div class="col-md-12">
                           <p>Your feedback has been submitted successfully.</p>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedBackBtn">
            <p role="button"><a href="https://bestpractice.bmj.com/topics/en-gb/151/treatment-algorithm#"><span class="material-icons"></span>&nbsp;FEEDBACK</a></p>
         </div>
      </div>
      <script type="text/javascript" src="../js/common.js"></script>
      <script type="text/javascript" src="../js/main.js"></script>
      <script>
         // Code for the recently viewed topics suggestion, needs to be inlined to use the Java values
         /*<![CDATA[*/       
         function dedupe(array) {
           var seen = {};
           return array.filter(function(item) {
               return seen.hasOwnProperty(item.id) ? false : (seen[item.id] = true);
           });
         }
         function TopicViewed(id, title, lang) {
           this.id = id;
           this.title = title;
           this.lang = lang;
         }
         jQuery(document).ready(function() {
           var topicId = 151;
           var topicLang = "en-gb";
           var topicTitle = "Non-ST-elevation myocardial infarction";
           if(topicId){
               
             var topicsViewed = [];
             if (localStorage.getItem("topicsViewed") !== null) {
               topicsViewed = JSON.parse(localStorage.topicsViewed);
             }
               
             topicsViewed.unshift(new TopicViewed(topicId, topicTitle, topicLang));// Add new topics at the beginning
             topicsViewed = dedupe(topicsViewed);// Remove duplicates
             if (topicsViewed.length > 15){// Drop if size is bigger than 15
               topicsViewed = topicsViewed.slice(0,14);  
             }
         
             localStorage.topicsViewed = JSON.stringify(topicsViewed);
           }
          });       
         /*]]>*/
      </script>
      <script type="text/javascript">
         _linkedin_data_partner_id = "103646";
      </script>
      <script type="text/javascript">
         (function()
         {var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);}
         )();
      </script>
      <script type="text/javascript" data-cfasync="false">
         (function(W,i,s,e,P,o,p){W['WisePopsObject']=P;W[P]=W[P]||function()
         { (W[P].q=W[P].q||[]).push(arguments)}
         ,W[P].l=1*new Date();o=i.createElement(s),
         p=i.getElementsByTagName(s)[0];o.async=1;o.src=e;p.parentNode.insertBefore(o,p)
         })(window,document,'script','//loader.wisepops.com/get-loader.js?v=1&site=qudyiEfMBd','wisepops');
         window.WisePopsLoaderCallback = function(wisepops) {
                         wisepops._storage.visits = wisepops._storage.visits.slice(0, 2);
                         wisepops._storage._saveVisits();
                       };
      </script>
      <noscript>
         <img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=103646&fmt=gif" />
      </noscript>
      <!--[if lte IE 7]><script>var isIE7OrOlder = true; </script><![endif]-->   
      <!--[if lte IE 9]><script type="text/javascript" src="/gzip_e7393341757851d76c3264b590cf5143/js/browserupdate.js" ></script>
      <![endif]-->
      <script src="../js/adsct.js" type="text/javascript"></script><script type="text/javascript" id="createCookie">(function(){var b="bestpractice.bmj.com\/topics\/en-gb\/151\/treatment-algorithm",a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};a("RefTrack",b,2);a("RefTrackGroup","bestpractice.bmj.com",2)})();</script><script type="text/javascript" id="copyText">function getSelectionText(){var a="";window.getSelection?a=window.getSelection().toString():document.selection&&"Control"!=document.selection.type&&(a=document.selection.createRange().text);return a}document.addEventListener("copy",function(a){dataLayer.push({event:"textCopied",clipboardText:getSelectionText(),clipboardLength:getSelectionText().length})});</script>
      <script type="text/javascript" id="facebookPixel">!function(b,e,f,g,a,c,d){b.fbq||(a=b.fbq=function(){a.callMethod?a.callMethod.apply(a,arguments):a.queue.push(arguments)},b._fbq||(b._fbq=a),a.push=a,a.loaded=!0,a.version="2.0",a.queue=[],c=e.createElement(f),c.async=!0,c.src=g,d=e.getElementsByTagName(f)[0],d.parentNode.insertBefore(c,d))}(window,document,"script","https://connect.facebook.net/en_US/fbevents.js");fbq("init","414393182248444");fbq("track","PageView");</script>
      <noscript><img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=414393182248444&amp;ev=PageView&amp;noscript=1"></noscript>
      <rc-c2d-menu class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF">
         <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05">
            <img class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dLogo--3d0gU" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFgAAABYCAYAAABxlTA0AAAAAXNSR0IArs4c6QAAB99JREFUeAHtnWtsVEUUx/+73T4ohUpBXgVKyysgGATFokIJUdCYEJD4waghBD4AfvAFNEbwFaM8DAmJiSbiAzTB+AECGgiEoAQiLwFJ5FlKodBSHi2U0kK77dY5S5e2S/feOXPvsC13TrLZvXfOnJnzu3PnzuvO+hAljSuRjRBmoRETRFAOfOguvlPEcWKUqjmUIOCL6DQ2wo+VWCJAfiQ+CZHz5tsZgTDgMNzl2CxMvezMnIkdTcAfPkEl18CNZuPKsa+pzi0w1YIrPO8z4m96oJk69z407pzwi5JLrQUjmghQHZyjybYxKwj4m9q5BoYmAlSCUzTZNmYFAaqDTQ9NY1EIaLMdSAUG5AF9xwMZw4AumUDnXkBSFyAxDUhIEpdXNF58d5vi2vLRGAJCDUBDHRC8BdRVAdWXgaoSoOIUULoXKN4F1NdoyYL7gLOnAmPfBrImA4FkLZlmGaULmEAfcaMmdb57kbsNbm2ivhY4vxM4tBoo2tY6zOGRr3GZqCTckD7jgCnfAL3HuGEtfjbKDgPb5wOXDriSBxfuT2EibznwprjVOjpcQko+kC/kk3hEORVnFqiefWUjkLtYf13q1FNOfKpWyCfyjXx0IA4Ai6jT1gNDpjlIvp1HJd/IRwclWR1w3pcPN9zItSfI5KuiqAGmB9rTCxWT7IDRyFfyWUHUAFNrQXf7VcEZbVHIV/JZQfiAqZ37MLQWuLDIZ/KdKXzA1Inwqij4zuvJUZOFemgSQr2XNYdL8euxMhy/Wo2K20GJWPpUEkVvLrNLMvKyuuHd3P4Y3kP06rgS7p0KBoxuNQ8wjS1IdH8Lr9/G3N9P4O8LN7guaNMPNoRw7sbt8Icu+tKJ2Xg/Nwv+e/PqEkmT78Tg7FYJ5bsqvCqCBm5s5HJ1HZ778Z92BTc6y7X1ISzZWYjFOwqig+yPJRi0NMIDTKNiNrJgy8m4Vwc2WbwX/PXBi9jDvcskGNxLQPzgAaYhRwvZee46/jh9zUKjfQU1igUh721nlmIbBtEe8gDTeK6FdCS4ETeOllWhpEoMV8qKDYNoMzzASV2j47c6LhIPkY4orHzThAFDeIATrZs2t+rEzEEHFFa+aTaGITzANM3jdWEy4AGmOTSvC5MBD7CXBnhiFSQmA15PLlaiCucnii7rvLHWzT4Fs+EotaLXNnvTcdXorsaLG+Cs9BTMHN7TVWcixqqD7edhy6siIh6Yb2kCBrA0KjVFA1iNm3QsA1galZqiAazGTTqWASyNSk3RAFbjJh3LAJZGpaZoAKtxk44Vt56cdA5bKG45U45Np662ONP2z2CDOyty27bOO9uhAB+9XIWf/i3leSih3Smgb5TQVBHiAvRPF9PxmsTzgDO7JiP7kU6a8HJnlbVlI36GXx/ZR7wqqE88XYJ7pyVj0TNZ+ugKy54FnCTWqq2dPgJdk/U94OjKeRJwekoA62eOxCQxq6JbOlQzzQ0Yuf3SsW76Y6AZlQchcQMcDPE7A8n0QqGiDM5Ixfwn+4lPJhJ8Oh9rrTMYN8CVd+pb50TiiObwfjhSioKKGgntZpVfZozEqyP0zP81p9L2L/Ui0YY9Tgm7oQCYbuv/5udi/5xxYl2vfCmkBeDxEh5gerHaQjhPZNZ6sKg0R/dOw+zRfaPOxj5cfaAYV6qDsRU0hvAA01vrFjKQ0SMqu1WLCzcZqxqj0v10Ug6oNSAj1WLN3Oe7i2RUXdfhAaYtASzk8V68hXEHS29aWLMOejQ1ER9OyLZWahH6fbjufvCrP3mAab8FC5k8MAM+Rt2472KlhTX7oLdEq2Bod7l3ietDISz9s9DeqMsaPMC0mYWF9OyciFE95UvxxpNXLKzZBwXEGywrnh9ir9ikQentK3F2UaUTa1LkAaadQmxk6qAMG43m4OLKO/jr/PXmEwq/XhrcHVMH0f6lcpK/44ycoktaPMC0DYuNzBO3LfXzZWXV3mJZ1Zh6K18YgoBfLk2qljactJ8ViZkYM0AuVxGjtMeNjfQTL/vNeUK+CbWtsByHL1lXPTZJYpiohxc8Jb9Sk+rieoWepF0+2grnAaYNhCQk/9mBSGFMw7yz/bSEVWuVJaJF0SNVbgX+GdET/PaQ/d1onaJcKA9weHcm+7Zrn7Sk8JuUclkA9ovbdo1oRjmR9OQAPsnLkTbxxZ4iVNbyu+vSCTQp8gDTO7q0O5OELBw/QPT/rV/7ammG3ro8cc1Zl5aqplGSbfHymiCW7TnfMgtafvMAUxZo6ytJoWHBuWMyQS9i233qxFT7GxuPoSZo3R23SpreO141ZWj4IWuXHoV/d6QExTfvWJl0HKa2rdesQ97cMyKCe7n8QBO/BFMitK+YzcBPJC9e/1YDTJu27f/K6+yk/FcDTKZ3fQAUbJZKxMtK6oDF3uTY/JqBbFN6HAAWlqnZtmEGsG+FqZNjgHYGOGxUlORd+cDP4wHaWNNIKwIuAG6yRw++tWOB314ECreK0m3f42uVk4f0QG7OheM87b9Ln5gbNIs9J2hbhAe1QTMn7zK6FbxxE7WOhkxGjE6YAP0LQXymWz1yAagO1tsZ9wjIWG7SvxCUxwo0550ToBJ81rkZYyEWAaqDd8cKNOedE/CLFcJrBWTrJTvO0/GsBb9vEYoE4M88S0Cz4+GRY/OXk/ooh7vKYrVTCPmYJqqLj0114S7s++Y+zN/+ugv4fzOpwZkATYhDAAAAAElFTkSuQmCC">
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v" title="Call with RingCentral">
               <svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 24 26">
                  <path fill="#0083BF" fill-rule="evenodd" stroke="#0684BD" stroke-width=".9" d="M6.656 17.651C.942 10.547.28 4.627 2.545 2.607c.592-.522 2.16-1.323 2.892-1.427.801-.14 1.602.243 2.02 1.01.802 1.636 1.777 3.238 2.788 4.805.452.697.348 1.567-.244 2.16-.349.348-.767.557-1.15.765a3.18 3.18 0 0 0-.801.523s-.105.104-.105.313c-.035.453.035 1.707 2.02 4.214 2.16 2.647 3.45 2.82 3.798 2.82.14 0 .244-.034.244-.034.244-.21.453-.453.662-.697.314-.348.593-.696 1.01-.975.697-.452 1.638-.348 2.16.21 1.325 1.323 2.753 2.576 4.112 3.76.662.557.906 1.428.557 2.16-.244.66-1.359 2.02-2.02 2.541-.558.488-1.324.697-2.195.697-3.345 0-7.7-2.925-11.637-7.8z"></path>
               </svg>
            </div>
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7 _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v"></div>
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v" title="SMS with RingCentral">
               <svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 22 21">
                  <path fill="#0684BD" fill-rule="nonzero" d="M10.944.014C4.91.014.007 4.068.007 9.316c0 2.86 1.54 5.626 4.085 7.417-.094.534-.377 1.257-1.162 2.64l-.692 1.131h1.383a6.976 6.976 0 0 0 4.84-1.917c.817.157 1.634.252 2.483.252 6.034 0 10.936-4.275 10.936-9.523 0-5.28-4.902-9.302-10.936-9.302z"></path>
               </svg>
            </div>
         </div>
         <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr">
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO"></div>
         </div>
      </rc-c2d-menu>
      <script src="../js/saved_resource.js" type="text/javascript"></script>
   </body>
</html>